

NICE OBSERVATIONAL DATA UNIT (ODU)

Commissioning Through Evaluation (CTE)
Percutaneous Occlusion of the Left Atrial
Appendage in Non-Valvular Atrial Fibrillation for
the Prevention of Thromboembolism (LAAO)

FINAL REPORT

Newcastle and York External Assessment Centre
(NY EAC)

Dr. Iain Willits, NUTH

Kim Keltie, NUTH

Dr. Sam Urwin, NUTH

Helen Cole, NUTH

Joyce Craig, YHEC

Professor. Nicholas Linker, NHS England Cardiac CtE Clinical Lead (LAAO)

Dr. Robert Henderson, NHS England Cardiac CtE Clinical Lead (PFOC)

Dr. Mark de Belder, NHS England Cardiac CtE Clinical Lead (MitraClip)

Dr. Andrew Sims, NUTH

15 February 2018

Project Name: Commissioning through Evaluation (cardiovascular procedures)
Project Number: RX085
Start Date: 12 September 2014
Output Date: 15 February 2018 FINAL SUBMISSION

Correspondence to: Dr. Iain Willits
NICE External Assessment Centre
Medical Physics Directorate
Freeman Hospital
The Newcastle upon Tyne Hospitals NHS Foundation
Trust (NUTH)
NE7 7DN
Tel: +44 (0)191 2137787

Commercial in confidence data are highlighted in yellow.

Declared interests of the authors: None

The views expressed in this report are those of the authors and not those of NICE. Any errors are the responsibility of the authors.

Contents

Executive Summary	3
Abbreviations	6
Section 1: Introduction	8
1.1 NHS England Commissioning through Evaluation – Left Atrial Appendage Occlusion (LAAO)	8
1.2 Description of the Procedure	11
Section 2: Methods	13
2.1 CtE LAAO Providers and Programme Governance	13
2.2 CtE LAAO Commissioning Details	14
2.3 Inclusion and Exclusion Patient Selection Criteria	14
2.4 Primary Data Collection	14
2.4.1 Database Details and Information Governance Arrangements	14
2.4.2 Active Surveillance	16
2.4.3 Case Eligibility Criteria	18
2.4.4 Data Cleaning	18
2.4.5 Outcomes Indicators	18
2.4.6 Statistical Analysis	19
2.5 Secondary Data Collection (Literature Review)	20
2.6 Research Design	23
Section 3: Results	29
3.1 Primary Data Collection (CtE Database)	29
3.1.1 Numbers of Patients Treated at Each Centre	29
3.1.2 Summary Statistics of Patient and Procedural Characteristics	29
3.1.3 Active Surveillance (Evaluation of Coverage)	29
3.1.4 Outcomes	32
3.2 Secondary Data Collection (Literature Review)	35
3.3 NHS England Questions	37
3.3.1 Question One	39
3.3.2 Question Two	46
3.3.3 Question Three	48
3.3.4 Question Four	50
3.3.5 Question Five	51
3.3.6 Question Six	52
3.3.7 Question Seven	54
3.3.8 Question Eight	54
3.3.9 Question Nine	55

3.3.10	Question Ten	56
3.3.11	Question Eleven	58
3.3.12	Summary of Answers to NHS England Questions	60
Section 4:	Discussion	63
4.1	Summary of Findings from Primary Data Collection (CtE Database)	63
4.2	Results in the Context of Other Studies	64
4.3	Limitations and Future Proposals	65
4.3.1	Limitations	65
4.3.2	Strengths	66
4.3.3	Future Proposals	66
Section 5:	Conclusion	67
Section 6:	Acknowledgements	69
Section 7:	References	70
Appendix 1 –	Data Flow Diagram	73
Appendix 2 –	Patient Characteristics	74
Appendix 3 –	Procedural Characteristics	77
Appendix 4 –	Outcomes	79
Appendix 5 –	Outcomes (Time to Event Analysis)	80
Appendix 6 –	Kaplan-Meier Curves	81
Appendix 7 –	Event by Device Manufacturer	82
Appendix 8 –	Cost of an LAAO Procedure	83

Executive Summary

Non-valvular atrial fibrillation (AF), the most common cause of abnormal heart rhythm, causes a five-fold increased risk of thromboembolic stroke. Oral anticoagulation drugs, such as warfarin and novel oral anticoagulants (NOACs), substantially reduce this risk; however, a proportion of people with AF cannot take these drugs due to absolute or relative contraindications, and treatment options for these people are limited. Left atrial appendage occlusion (LAAO) is a non-pharmacological option for reducing the risk of stroke in patients with AF. It is a percutaneous surgical intervention that aims to reduce the risk of thromboembolic stroke by mechanically blocking the entrance to the appendage of the left atrium, which is known to be a frequent source of thromboembolism in patients with AF.

Although the safety and efficacy of LAAO has previously been investigated, real-world data generalisable to the UK NHS are limited. In order to evaluate the procedure, NHS England set up a multi-centre observational registry using the process of Commissioning through Evaluation (CtE). The registry was designed to include patients with AF with absolute or relative contraindications to anticoagulation and considered to be at high risk of thromboembolic events. The registry recorded a range of clinical outcomes with a maximum follow up of 2 years. The aims of the CtE registry were to provide data on the safety, efficacy and costs of LAAO in a real-world setting, and specifically to answer 11 pragmatic questions concerning these issues. As the registry was single-armed, a parallel literature search was undertaken in order to present the registry findings in the context of published studies in other populations and settings, and to assess whether procedural outcomes were consistent with previously reported studies. Information gained from the registry will be used to inform future commissioning decisions.

In total, 525 patients were eligible for analysis (median CHA₂DS₂-VASc of 4), with 70.2% (85/121) of patients reaching 2 years since their LAAO device implantation reporting follow up data at 2 years. Around 18% of patients were receiving oral anticoagulation immediately before the procedure, but this dropped to around 3% after 2 years follow up. The registry reported a [technical success rate](#) of 93.6% (95% CI 91.1% to 95.6%) and a [procedural success rate](#) of 89.0% (95% CI 86.0% to 91.6%). There was an in-hospital major complication rate of 5.5% (95% CI 3.7 to 7.8%). The rate of procedural mortality was low (1%), with a reported neurological event rate of 0.8% (95% CI 0.2 to 1.9%). These short-term results were consistent with values from RCTs and observational studies reported in the literature.

In the medium term, the registry reported a composite of death and neurological event rate of 9.8 (7.0 to 13.4) per 100 person-years, over a total aggregated follow-up period of almost 400 person-years. Following discharge from hospital, there were 10 ischaemic neurological events, giving a rate of 2.6 (95% CI 1.3 to 4.8) per 100 patient-years. Two deaths were attributed to ischaemic stroke. These results were numerically lower compared with historic data from epidemiological studies (CHADS₂ and CHA₂DS₂-VASc scores). Although the neurological and ischaemic event rates were higher than reported by the PROTECT-AF and PREVAIL RCTs, results from these studies were not considered generalisable due to fundamental differences in the study population and intervention. That is, patients in the CtE registry had a greater number of comorbidities and were at greater risk of ischaemic stroke

than those in the published clinical trials, and most patients were unable to receive warfarin as part of the intervention.

In conclusion, the CtE registry has reported data that show that the LAAO procedure is procedurally successful in about 9 out of 10 patients and is associated with a decreased risk of ischaemic event compared with historical epidemiological data in patients with a similar baseline risk. Currently, there is a lack of comparative, generalisable trial data to demonstrate the procedure is effective compared with an equivalent population. This issue may be resolved with the publication of the on-going ASAP TOO trial.

Any clinical benefits of LAAO should be considered in the context of an estimated cost per procedure of £11,600 (range of £9,500 to £13,300). These costs were estimated using information gathered using templates completed by sites managing patients in the registry. These costs include the cost of devices using a cost for each device provided by NHS Supply Chain. The unit cost includes overheads of 3% for its internal costs. A further 15% has been added to the NHS Supply Chain price for NHS procurement and stores related costs plus property, finance and management related overheads.

A cost consequences analysis using a *de novo* economic model was undertaken to compare LAAO plus medical therapy with medical therapy only. Patients entered the model aged 75 years, consistent with the registry and flowed through the model for 15 years, to aged 90 years. Patients could be in a stroke free state, experience a neurological event (ischaemic or haemorrhagic stroke or transient ischaemic attack) or die. Other events modelled were subsequent stroke or transient ischaemic attack and bleeds. In the LAAO arm, patients had a risk of strokes and bleeds at the rates observed at up to two years in the CtE registry. These rates were extrapolated to 15 years. Patients in the comparator arm received medical therapy only and were estimated to have stroke and bleeding risks in accordance with their baseline CHA₂DS₂-VASc and HAS-BLED risk scores. The main cost drivers were the procedure costs for the LAAO pathway, (£11,600 central estimate) and the costs of managing strokes in the NHS and social care. These were based on patient-level health and social care costs, over five years, for virtually all patients admitted to hospital with stroke in England and hence reflect current funding rules across the two sectors.

The results reported estimated NHS costs per patient of £14,960 with LAAO and £8,390 for medical therapy over a 15-year period. The benefit to the NHS from avoided stroke management and medication costs of almost £5,050 per patient with LAAO were insufficient to offset the initial procedure costs of about £11,620 per patient. Hence LAAO was cost incurring for the NHS by about £6,570 per person.

Adopting a wider NHS and social care perspective increased the savings from avoided strokes as the majority of costs to manage patients with stroke (60% of the total) are incurred in social care settings. Total NHS and social care costs per patient, over 15 years, were similar between the LAAO pathway (£17,835) and medical therapy (£17,905), a potential saving of £70 with LAAO.

Forecast patient benefits from the procedure were material. For a cohort of 1,000 patients the total number of strokes was forecast to reduce by 68% from over 500 to around 160 over 15 years following the LAAO procedure. This was associated with 100 fewer deaths.

With cost consequences analysis, the decision makers do not have a threshold-based decision rule to inform their decisions on cost effectiveness. Hence it is not possible for the EAC to advise from an NHS perspective, whether the additional cost to the NHS of about £6,570 is cost-effective, given the forecast savings in strokes and deaths.

Adopting the wider NHS and social care perspective, the EAC can conclude the LAAO procedure is cost-effective compared to medical therapy. Costs are broadly equivalent between the two arms and LAAO is associated with material clinical and patient benefits from avoided strokes and associated reduced mortality.

Abbreviations

ACP	AMPLATZER Cardiac Plug
A + C	Aspirin and clopidogrel
AF	Atrial fibrillation
ASD	Atrial septal defect
BIA	Budget impact analysis
BP	Blood pressure
CCF	Congestive cardiac failure
CG	Clinical guideline
CHA ₂ DS ₂ -VASc	Risk calculator for stroke in people with AF, supersedes CHADS ₂ . Risk factor inputs are congestive heart failure, hypertension, age (2), diabetes, previous stroke or TIA (2), vascular disease.
CHADS ₂	Risk calculator for stroke in people with AF. Risk factor inputs are congestive heart failure, hypertension, age, diabetes, previous stroke or TIA (2).
CI	Confidence interval
CrI	Credibility interval
CtE	Commissioning through Evaluation
CVA	Cerebrovascular accident
DM	Diabetes Mellitus
EAC	External Assessment Centre
EACTS	European Association for Cardio-thoracic Surgery
eGFR	Estimated glomerular filtration rate
EQ-5D-5L	Euroqol 5 dimensions 5 levels
EHRA	European Heart Rhythm Association
ESC	European Society of Cardiology
EQ-5D	EuroQol 5 dimensions
EVPI	Expected value of perfect information
FU	Follow up
HAS-BLED	Risk calculator for major bleed for patients with AF on anticoagulation. Risk factor inputs are hypertension, renal disease, liver disease, stroke history, labile INR, age, medication, alcohol or drug use.
HES	Hospital episode statistics
HR	Hazard ratio
ICER	Incremental cost-effectiveness ratio
INR	International Normalized Ratio
IPG	Interventional procedures guidance
IQR	Inter-quartile range
ITT	Intention to treat
LAA	Left atrial appendage
LAO	Left atrial appendage occlusion
LVEF	Left ventricular ejection fraction
MDS	Minimum data standard
MDT	Multi-disciplinary team

MeSH	Medical subject headings
MI	Myocardial infarction
MSS	Medium to severe stroke
NHS	National Health Service
NICE	National Institute for Health and Care Excellence
NICOR	National Institute for Cardiovascular Outcomes Research
NOAC	Novel oral anticoagulation drug
NYHA	New York Heart Association (grade)
OAC	Oral anticoagulants
ONS	Office for National Statistics
OR	Odds ratio
PFO	Patent foramen ovale
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
PSSRU	Personal Social Services Research Unit
PY	Person-years
QoL	Quality of life
QALY	Quality adjusted life year
RCT	Randomised controlled trial
RIND	Reversible ischemic neurological deficit
SD	Standard deviation
SE	Systemic embolism
TIA	Transient ischaemic attack
TOE	Transoesophageal echocardiography
WTP	Willingness to pay

Section 1: Introduction

1.1 NHS ENGLAND COMMISSIONING THROUGH EVALUATION – LEFT ATRIAL APPENDAGE OCCLUSION (LAAO)

NICE provides support to NHS England in [Commissioning through Evaluation \(CtE\)](#):

“NHS England’s Commissioning through Evaluation (CtE) programme enables a limited number of patients to access treatments that are not funded by the NHS, but nonetheless show significant promise for the future, while new clinical and patient experience data are collected within a formal evaluation programme.”

The work commissioned by NICE (‘Project RX085’) from Newcastle and York (NY) EAC comprises evaluation of three percutaneous cardiac procedures:

- Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism ([NICE IPG349](#), June 2010). Shortened term used is ‘LAAO’;
- Percutaneous Closure of Patent Foramen Ovale to prevent recurrent cerebral embolic events ([NICE IPG472](#), December 2013). Shortened term used is ‘PFO Closure’;
- Percutaneous mitral valve leaflet repair for mitral regurgitation (MitraClip) ([NICE IPG309](#), August 2009). Shortened term used is ‘MitraClip’.

A Cardiology CtE Steering Group is established as a subgroup of the NHS England [Cardiothoracic Services Clinical Reference Group \(CRG\)](#). It reports to the [Programme of Care Board for Internal Medicine](#) for NHS England. Three Individual Technology Groups report to the CtE Steering Group on the progress of the above three specialised cardiological interventions which form the cardiac CtE programme.

The National Institute for Cardiovascular Outcomes Research (NICOR) was contracted by NY EAC to design and host an on-line registry for LAAO procedures, to provide a project management function to promote data entry quality and completeness by commissioned CtE provider sites and to link registry data with Hospital Episode Statistics (HES) and Office of National Statistics (ONS) mortality datasets. NICOR and the EAC consulted the LAAO Individual Technology Group in the design of the LAAO registry. NICOR were the formal data owner of the registry, and were the applicant to NHS Digital for data linkage with HES and ONS.

NY EAC's objectives in Project RX085 from NICE were to:

- Review existing registry data fields in each dataset and advise on their suitability for updating and developing NICE guidance;
- Advise on the appropriateness of registry data fields for each dataset being proposed or considered in relation to clinical and cost effectiveness outcomes to enable NICE to provide NHS England with further data to help inform future commissioning decisions for the procedures;
- Establish processes to a) ensure on-going review of the LAAO dataset quality, completeness and coverage, with action plans for improvements where needed and b) deliver regular evaluative reports that are useful for decision making;
- Update the literature searches since publication of each NICE interventional procedures guidance (IPG) in order to identify publications of relevance;
- Manage the contract with NICOR and participate in the CtE Steering Group for cardiovascular procedures;
- Develop a protocol for analysis of data and consult with key partners (listed above) to gather views on the proposed methodology and proposed outputs;
- Produce a final report (not intended for publication) answering the CtE evaluation questions set by NHS England (tabulated below);
- Present findings in the form of a publishable paper (to be submitted for peer review for a high impact journal). This should be of a standard to be included as an input in the evidence base of the NICE technology appraisals programme (<http://www.nice.org.uk/article/PMG9/chapter/Foreword>);
- Advise on further research that might be needed to generate clinical and cost effectiveness evidence in line with methods used in NICE evaluation programmes, including suitable study designs for such research.

Outputs required by NICE from NY EAC and delivered prior to this final report were:

- Output One - [1] a report for presentation to the CtE Steering Group on all three procedures, analysing the coverage, quality and completeness of the register to date, and making preliminary recommendations about the definitive dataset to inform NHS England's contracts for the procedures with the specialist centres, and to meet NICE's needs in relation to updating guidance. **Completed 28/11/2014;**
- Output Two - [2] a report for submission to the CtE Steering Group for cardiovascular procedures and collaborating partners proposing: a) a process to ensure on-going review of the database quality, completeness and coverage, with action plans for improvements where needed and b) the format of evaluative reports designed to be useful in informing decision making for guidance development. **Completed 04/02/2015;**
- Output Three - [3] a report for submission to NICE and the CtE Steering Group proposing a draft protocol for analysis of data that describes the methods that will be used to compare effectiveness of each of the procedures between propensity-matched cohorts of patients undergoing the range of treatment options (including cost analysis). This will have been circulated for consultation with key partners (listed above) and adjusted as appropriate prior to presentation to NICE. **Completed 31/03/2015.**

The above three outputs from the project, all of which were shared with the CtE Steering Group and approved by them, are used as source material for the general background and [methods](#) sections of this final report from NY EAC to NICE.

The NHS England questions for CtE of LAAO were originally presented to NICE, discussed with NY EAC, and edited to the final form presented in the [Table 1](#).

Table 1: Left Atrial Appendage Occlusion (LAAO) in Patients with Atrial Fibrillation.

Questions from NHS England	Final version of question, as amended NICE following discussion with EAC
1. Can UK clinical teams reproduce the success rates for left atrial appendage occlusion reported in existing clinical trials, with equivalent or lower complication rates?	Can UK clinical teams reproduce the short and medium success rates for left atrial appendage occlusion reported in existing clinical trials, with equivalent or lower complication rates?
2. Does left atrial appendage occlusion offer these patients a lower risk of stroke or other embolic clinical events compared to those that would have been predicted on the basis of validated risk scores?	Does left atrial appendage occlusion offer patients a lower risk of stroke or other embolic clinical events in the short and medium term compared with those that would have been predicted on the basis of validated risk scores?
3. Is left atrial appendage occlusion associated with an improved quality of life for these patients?	Is left atrial appendage occlusion associated with an improved quality of life?
4. Are there any longer-term cardiac complications associated with the use of these devices (e.g. erosion with penetration through the wall of the atrium)?	N/A unless an extended time period for the project is agreed.
5. How many patients with atrial fibrillation with a contra-indication to oral anticoagulants, or who have had a stroke whilst on oral anticoagulants, or who have had a significant bleed whilst taking oral anticoagulants are candidates for left atrial appendage occlusion? i.e. if LAAO for patients with AF who cannot take anticoagulants becomes routinely commissioned, what is the likely clinical need??	How many patients with atrial fibrillation with a contra-indication to oral anticoagulants (including previous significant bleed), or who have had a thromboembolic event despite being on oral anticoagulants, are candidates for left atrial appendage occlusion?
6. Do the commercially available current devices perform equivalently?	Which devices are used to undertake LAAO and what are the device-specific efficacy and safety outcomes in CtE funded patients undergoing the procedure?

Questions from NHS England	Final version of question, as amended NICE following discussion with EAC
7. Is the frequency of complications sufficiently low to provide a positive risk-benefit ratio?	Is the frequency of complications seen with the intervention clinically acceptable? (This question has already been considered by the NICE Interventional Procedures Advisory Committee when developing the IP guidance on this procedure. If the CtE project indicated that this procedure has a more risky safety profile than appears in the current NICE Interventional Procedures guidance, it could potentially lead to NICE updating the guidance, in line with normal processes).
8. What are the characteristics of patients who are successfully treated compared to those in whom treatment is unsuccessful? Are there subsets of patients who get a particularly advantageous result? Conversely, are there subsets of patients for whom this treatment is not effective? Do patients of different gender or from different ethnic origins respond equivalently?	Are clinical outcomes from left atrial appendage occlusion associated with particular patient characteristics (clinical or demographic)?
9. What is the true procedural cost of left atrial appendage occlusion in the NHS?	What are the full procedural costs of left atrial appendage occlusion to the NHS?
10. What costs savings might occur in the NHS as a result of left atrial appendage occlusion?	What are the potential cost savings for the NHS through provision of left atrial appendage occlusion for appropriate patients?
11. What is the cost-effectiveness of left atrial appendage occlusion based on UK procedural and follow-up costs?	Is left atrial appendage occlusion cost-effective from the perspective of the NHS?

1.2 DESCRIPTION OF THE PROCEDURE

The LAAO procedure is described in [NICE IPG349](#):

“Percutaneous occlusion of the LAA is usually carried out with the patient under general anaesthesia. Using fluoroscopic guidance, a catheter is advanced through the femoral vein into the right atrium and then into the left atrium via a transseptal puncture. The location of the LAA is confirmed and the size of the LAA orifice is established by transoesophageal echocardiography (TOE). An appropriately sized device is selected and deployed in the mouth of the LAA where it is expanded to fit the space.

The position and patency of the occlusion device may be confirmed postoperatively using echocardiographic imaging.”

There are currently three CE marked devices that are eligible for the CtE programme, available and used in the UK:

- The 'WATCHMAN' device marketed by Boston Scientific;
- The 'AMPLATZER Cardiac Plug (ACP)' and 'AMPLATZER Amulet' marketed by St. Jude Medical (now owned by Abbott).

Percutaneous LAAO received a positive recommendation with normal arrangements from NICE ([IPG349](#)). The guidance recommended that the procedure should be undertaken under the direction of a multi-disciplinary team experienced in the management of patients with atrial fibrillation (AF) at risk of stroke. NICE IPG349 does not clearly define which patients should be eligible for LAAO, but states selection should be performed by a multi-disciplinary team and 'Patients should be considered for alternative treatments to reduce the risk of thromboembolism associated with AF, and should be informed about these alternatives'.

Section 2: Methods

2.1 CTE LAAO PROVIDERS AND PROGRAMME GOVERNANCE

Hospitals providing the CtE procedures in the 10 centres participating in the LAAO scheme are:

- Barts Health NHS Trust and The Heart Hospital, University College of London Hospital NHS Foundation Trust;
- Brighton & Sussex University Hospitals NHS Trust;
- Guy's and St Thomas' NHS Foundation Trust;
- Kings College Hospital NHS Foundation Trust;
- Leeds Teaching Hospitals NHS Trust;
- Liverpool Heart & Chest Hospital NHS Foundation Trust;
- Oxford University Hospitals NHS Trust;
- The Newcastle upon Tyne Hospital NHS Foundation Trust and South Tees Hospitals NHS Foundation Trust;
- University Hospitals Leicester NHS Trust;
- University Hospital of North Staffordshire NHS Trust.

The criteria used to select the hospitals for the CtE work considered a number of competing factors and are described in the NHS England Specialised Services Circular (SSC) 1453 for LAAO [4]. An advisory panel made recommendations to NHS England as to which providers should be selected to be CtE centres. The final selection of centres was undertaken by the regional Medical Directors.

The NHS England Cardiac CtE Clinical Lead for LAAO is Professor Nicholas Linker, Consultant Cardiologist, South Tees Hospitals NHS Foundation Trust. Professor Linker is Chair of the NHS England LAAO Individual Technology Group. The role of the Group, set out in its Terms of Reference (ToR), is to:

- Work with the EAC and NICOR on the development of the relevant dataset;
- Define and clarify patient access criteria, where required, within the terms of the published policy statements / specification;
- Ensure that all participating centres are collecting, verifying and uploading data in a timely manner;
- Ensure that all participating centres are collecting follow-up data appropriately;
- Monitor performance of all centres performing procedures as part of CtE and report any concerns to the Steering Group;
- Monitor referrals, patient pathways and waiting times for the relevant procedure at all participating centres (including pathways for patients who do not receive the CtE treatment).

2.2 CTE LAAO COMMISSIONING DETAILS

NHS England commissioned a total of 300 LAAO procedures in each full financial year of the cardiac CtE scheme. Each of the 10 centres was required to do no more than 30 procedures per year. As CtE commenced on 01/10/2014, each centre could do no more than 15 LAAO procedures in 2014/15. Funding was made available by NHS England for each centre to do 30 procedures in 2015/16, making 45 procedures per centre in total.

Owing to slower than anticipated roll-out of the programme, some centres were permitted, by NHS England Specialised Services Circular SSC 1669 (November 2016), to carry on with their 2015/16 activity plans in financial year 2016/17, up to the contracted number of 450 procedures in total for the LAAO CtE programme.

2.3 INCLUSION AND EXCLUSION PATIENT SELECTION CRITERIA

According to the NHS England Specialised Services Circular (SSC) 1453 for LAAO [4], patient selection criteria were:

- Patients with atrial fibrillation at high risk of thromboembolic stroke (CHA₂DS₂-VASc score of 2 or more) with a contraindication to oral anticoagulation (intolerance, previous significant bleed, high bleeding risk) or evidence of a thromboembolic event in spite of adequate oral anticoagulant therapy;
- Patients can be referred by cardiologists, stroke physicians or other specialists in secondary care to the multidisciplinary team in a specialist cardiac centre. Direct referrals to cardiac centres from primary care and general practice requesting consideration for LAAO will not be accepted;
- Appropriate left atrial appendage morphology and suitability for a trans-septal procedure;
- Patient fully informed and consent provided.

Therefore, in summary, the LAAO procedure was commissioned for those with a contraindication to anticoagulants (including the 'new' anticoagulants apixaban, dabigatran, edoxaban and rivaroxaban), or for those receiving adequate anticoagulants but still experiencing a thromboembolic event.

2.4 PRIMARY DATA COLLECTION

2.4.1 Database Details and Information Governance Arrangements

NICOR worked with the CtE LAAO Individual Technology Group and NY EAC to produce the final dataset for LAAO.

NY EAC produced 'RX085 Output One - Recommendations on three NHS England Commissioning through Evaluation (CtE) registry draft datasets for MitraClip, LAAO and PFO Closure cardiovascular procedures' (November 2014) [1]. This identified and appraised new evidence added to the literature base and public domain since the original [NICE IP310/2](#) overview [5] was published and compared findings against the data fields contained in the draft LAAO CtE dataset.

The final LAAO dataset was developed into the online database by NICOR and the latest version may be downloaded as a Microsoft Excel® spreadsheet ([last updated 13/05/2016](#)).

Regarding information governance arrangements, as Data Controller, NICOR's responsibilities were:

- To ensure that a dataset being proposed or used for national data collection has appropriate independent oversight, and that all relevant data will be made available to NICE for use in developing guidance;
- To provide NY EAC with a monthly download of episode level full raw data sets from each registry (outwith normal NICOR data sharing policy and following the 'Use of Data' principles agreed with NY EAC). Data cleansing will happen to usual NICOR schedule. Monthly downloads may be aggregated or incremental. The EAC will provide feedback to NICOR on any data quality / completeness issues observed in the monthly raw data downloads;
- To arrange and undertake data linkage with Hospital Episode Statistics (HES) and Office of National Statistics (ONS) mortality data and provide complete data extract(s) to NY EAC in order to check for extra safety and efficacy, clinical effectiveness or resource utilisation information;
- To arrange and maintain appropriate EQ-5D-5L licensing arrangements to cover all projected patient volumes commissioned by NHS England in its CtE programme. This should include all commissioned follow up visits;
- To provide a telephone helpdesk service for answering technical enquiries / requests and for individual registration and access to each registry web portal. Clinical enquiries will need to go to the NICOR project manager and NY EAC may be co-opted to help NICOR respond to clinical or scientific queries;
- To operate within the general principles of Good Clinical Practice (GCP) in research, as outlined in the Research Governance Framework for Health and Social Care 2005;
- To make all necessary applications to comply with information governance requirements. These include but are not restricted to:
 - i. Complete the Information Governance Statement of Compliance process to the satisfaction of the NHS Health and Social Care Information Centre;
 - ii. Demonstrate compliance with the Data Protection Act 1998. This is also particularly relevant when data will leave or enter the EU. Appropriate regard needs to be paid to international regulations;
 - iii. Complete the Confidentiality Advisory Group application process to comply with the NHS Health Research Authority requirements for Section 251 approval.

2.4.2 Active Surveillance

NICOR provided NY EAC with their Minimum Data Standard (MDS) Summary Document for Cardiac CtE (**Confidential**). Some of the background detail is extracted in the below summary:

“While NICOR undertakes a number of manual and automated data quality control processes, the responsibility for data quality is shared with clinicians and organisations undertaking procedures in the NHS. It is particularly important that data are collected for patients who experience adverse outcomes (such as death, stroke, bleeding) and harm. NICOR aims to further assist organisations in their data submissions by defining a minimum data standard (an acceptable standard for data submissions to be measured against), to provide feedback to the provider organisations on the data quality of their quarterly submissions and to give organisations the opportunity to improve and resubmit the data should improvements be required.”

The final NICOR MDS for LAAO CtE baseline data completeness monitoring contained 30 key fields. Six additional fields were monitored for patient completion of EQ-5D questionnaires and EuroQol data entry (NICOR field identifiers 4.04 to 4.09). These are summarised in [Table 2](#):

Table 2: Fields in registry used for monitoring of data completeness

NICOR Field identifier	Data Field
1.03	NHS Number
1.06	Birth date
1.07	Sex
1.10	Postcode
2.03	Reason for treatment
3.01	Prev MI
3.06	CCF
3.13	DM
3.14	Hypertension
3.15	History of CV or other neurological disease
3.20	Previous peripheral embolism
3.21	Alcohol consumption
3.23	Renal transplant
3.25	Significant liver disease
3.26	Previous bleed
4.03	Date EuroQol form filled
4.04	EuroQol Mobility
4.05	EuroQol Self-care
4.06	EuroQol Usual activities
4.07	EuroQol Pain / discomfort
4.08	EuroQol Anxiety / depression
4.09	EuroQol Health state today
5.01	Current medication
5.02	Concomitant NSAID use

NICOR Field identifier	Data Field
8.10	Aortic atheroma in arch
9.01	Date of admission
9.03	Date/time of procedure
9.12	Consultant responsible
9.32	Device used
9.37	Device deployed successfully
10.02	Device embolization
10.05	Surgical intervention
10.11	Stroke (in-house)
10.20	Life status
10.21	Discharge date
10.23	Successful procedure, no complications

The six follow-up MDS fields for LAAO data completeness monitoring at 6 weeks were:

- 11.01 Date of 1st FU
- 11.04 Device still in situ
- 11.11 Death
- 11.16 Neurological event
- 11.23 Oral anticoagulant discontinued
- 11.24 Date 6 week EuroQol form filled

The equivalent variables were also monitored for follow up data at 6 months, 12 months and 24 months.

Summary reports were submitted to NICE by NY EAC on a quarterly basis, to a standard reporting template agreed with NHS England for all CtE projects. Key parameters for each CtE provider were:

- Contracted activity to date: the amount of CtE activity the centre should have performed by this point, according to their contract with NHS England.
- Actual activity to date, as identified through both register entries and active surveillance by NICOR collating a [SurveyMonkey](#) questionnaire from the CtE providers.
- Number of cases submitted to the NICOR registry to date. This number could be lower than the above actual activity to date, since active surveillance could identify cases that had not yet been registered.
- Number of cases identified through active surveillance but for which data were not yet submitted to the registry (i.e. the difference between the two previous figures).
- Initially, data completeness (%) was calculated for the subset of all LAAO records where the CtE provider had selected the 'CtE=Yes' check box when submitting the case to the NICOR dataset (this is the 'Number of cases' denominator, below):

$$\text{Data completeness (\%)} = \frac{\text{Number of completed entries in MDS data fields}}{\text{Number of cases}} \times 100$$

Later, queries from the CtE providers on this denominator led to refined definitions for Activity, Coverage, Completeness and Follow up (FU) reported. The final defined measures were:

- Activity: The number of CtE procedures recorded with a procedure date between 01/10/2014 and the date of raw data extract that had an eligible reason for treatment;
- Coverage: The percentage of patient follow ups reported out of the number of patients reaching the follow up time point in question. A 'reported' follow up had data in any of the MDS follow up fields for the time point in question;
- Completeness: The percentage of fields with any data out of the number of MDS fields for the time point in question;
- FU reported: This number included patients reported to have died since the previous follow up visit.

2.4.3 Case Eligibility Criteria

Inclusion criteria: All pseudonymised NHS procedures recorded in the LAAO CtE registry conducted between 1st October 2014 to 10th August 2017 with recorded reasons for treatment including: previous bleeding without anticoagulant therapy, previous bleeding with anticoagulant therapy, embolic event in spite of oral anticoagulant, intolerant of oral anticoagulant, poor control of oral anticoagulation, or at risk of severe bleeding.

Exclusion criteria: Procedures with missing procedure date.

2.4.4 Data Cleaning

Detailed methods of variable cleaning are described in *Supplementary Material - Table 1*. Data completeness and summary statistics, in terms of distribution of responses, were conducted for each of the data fields available and used to inform variables used and definition of outcomes during the statistical analysis.

2.4.5 Outcomes Indicators

a. Clinical

Primary outcome measures (detailed in *Supplementary Material - Table 2*) included: device implanted, in-hospital major complications, in-hospital minor complications, extended length of stay (2 or more nights in hospital), post-discharge clinical failure, post-discharge major complications and post-discharge minor complications.

Secondary outcome measures included: death, neurological event, pericardial effusion, embolization, additional intervention, major vascular complication, major bleeding complication, myocardial infarction (MI), acute kidney injury (AKI), endocarditis, device malfunction, device malposition, minor vascular complication, pericardial effusion (conservatively treated), procedural-related arrhythmia, minor bleeding complication, peripheral embolism and oesophageal damage.

b. Cost / resource

A bottom-up costing study of each stage in the pathway to insert LAAO devices was conducted. NY EAC firstly reviewed the draft Excel® costing template provided by the NHS England LAAO Individual Technology Group. Amendments were agreed with the Chair of the Group and the final template provided the 10 centres with detailed instructions on inputting the resources required to conduct each of the three stages in the relevant pathway being:

- Pre-operative assessment;
- Peri-operative procedure;
- Post-operative management.

The findings from the completed templates on resource use were reviewed by all authors and compared with existing clinical pathways. Where possible, outcomes reported in the LAAO dataset such as number and type of device implanted, type of imaging conducted at each stage in the pathway, procedure duration, primary and secondary operator and length of stay were used. Where such information was not available the three clinicians reached a consensus view on the appropriate resources required. Unit costs from NHS national datasets and other English national cost sources were applied to the resources and aggregated to give a total procedural cost. Sensitivity analyses were conducted to provide a high and low range of estimated costs. Full details are provided at [Appendix 8](#), with a summary of results in Tables 7 and 8.

c. Patient experience

From the outset of the cardiac CtE project, it was intended that EQ-5D-5L questionnaires would be issued to all patients at baseline procedure and all subsequent follow-up visits. This should allow pairwise analysis of results over the follow up period. However, as LAAO is a preventative procedure rather than a therapeutic one, it is unclear whether any symptoms of the condition (atrial fibrillation) would be improved, other than the possibility of reduced anxiety and reduced adverse effects of drugs or, less commonly, reduced quality of life following stroke or embolism.

2.4.6 Statistical Analysis

All scripts for case ascertainment, cleaning, processing and statistical analysis were written in the statistical programming language R [6].

Patient demographics, pre-operative clinical scores and procedural details were compared between the whole cohort and the subgroup of patients with any information recorded from follow-up appointments (at 6 weeks, 6 months, 1 year or 2 years). Fisher's exact tests or Mann Whitney U-tests were used as appropriate. Bonferroni correction was used to adjust the level of significance to take into account multiple comparisons.

Exploratory univariate and exploratory multivariate analysis were conducted for the defined outcome measures. Univariate analysis was conducted for each outcome measure and up to 27 covariates. Bonferroni correction was used to adjust the level of significance to take into account multiple comparisons (between outcome measure and each covariate of interest). Multivariate analysis used generalised linear modelling with binomial error distribution in order to estimate the effect size of covariates. Numeric covariates were centred on their median before inclusion in multivariate analysis, if appropriate. Binary logistic regression analyses were checked for convergence and over-fitting, and either modified (e.g. by reducing the number of covariates) or reported as not valid.

Crude incidence rates for death, neurological events, combinations of death and/or neurological events, peripheral embolism and device malposition recorded during the study period were calculated as the number of events per 100 person-years of follow-up. Kaplan-Meier analysis was applied to the time from procedure to the time of the death, first neurological event and the combination of death or first neurological event. Patients who suffered no events and were alive at the end of the study were considered censored.

Paired quality of life scores and utilities were compared at each time interval (6 weeks, 6 months, 1 year, 2 years) against pre-operative scores using Fisher's tests or t-tests where appropriate.

2.5 SECONDARY DATA COLLECTION (LITERATURE REVIEW)

The aim of the final LAAO literature review for CtE was to identify key published studies in patients with non-valvular atrial fibrillation (AF) and summarise results so they align with the requirements of the outputs of NY EAC project RX085, including the 11 questions set by NHS England. A brief summary of the review methods is presented here. A standalone literature review document is available for further information (Willits *et al.*, LAAO literature review document [unpublished], November 2016) [7].

Firstly, a literature search was performed from March 2010, which was the search date of the original [NICE IP310/2](#) overview that informed [NICE IPG349](#). The NICE search strategies for replication were sourced through documents supplied by NICE and through communication with the Senior Information Manager at NICE Guidance Information Services. The EAC team and NICE agreed that no quality assessment would be made of the NICE strategies and the intention was to use the NICE-designed strategies as supplied. Some minor edits were made (for example, the correction of a line-combination error identified in an original strategy, the addition of device trade names not included in the original searches, the deletion of the trade name for a device which never became commercially available / CE marked, and edits to index terms due to changes in MeSH / Emtree indexing). Apart from these minor changes, the terms used in the update strategies reflected those used in the original strategies of [NICE IPG349](#).

The scope of the literature review was intended to broadly reflect the population and intervention covered in the CtE registry. The scope, described in PICO (Population, Intervention, Comparator, Outcomes) format, is summarised in the [Table 3](#).

Table 3: Scope of literature review

Domain	Terms identified from title or abstract	Comment
Population	Patients with atrial fibrillation at high risk of thromboembolic stroke eligible for LAAO.	NHS England specifies LAAO indicated only in patients with contraindications to anticoagulation or anticoagulation not effective. However, this limit might exclude important studies and population needs to be expanded in order to answer NHS England questions.
Intervention	LAAO	All percutaneous endocardial devices to be included. Known devices recorded in the LAAO registry to 31/07/2016 are WATCHMAN (Boston Scientific), AMPLATZER Cardiac Plug / AMPLATZER Amulet (St. Jude Medical) and WaveCrest (Coherex)
Comparator	Any or none	Single arm observational studies will be considered (e.g. registries)
Outcomes	Clinical outcomes Utility and resource use outcomes*	Surrogate and non-clinical outcomes will be excluded.
Study type	All primary studies Secondary studies (systematic reviews and meta-analyses) Economic studies*	Non-systematic reviews, editorials and opinion pieces excluded. Abstracts excluded.

*Economic studies and associated outcomes to be identified for possible future reference.

Given the timelines of the project and the purpose of the update search, the EAC team and NICE agreed that only the bibliographic databases listed in [Table 4](#) would be searched. In addition, it was agreed that strategies would be limited to results published in English language only, and that conference-related publication types would be excluded from the Embase search.

Where database functionality allowed, results were limited to records added to the database since the date of the last search, using appropriate fields such as the entry date field in MEDLINE. Where database functionality did not allow this, results were limited by publication date, reflecting the pragmatic context of the search.


Table 4: Bibliographic databases searched

Database / information source	Interface / URL
MEDLINE and MEDLINE In-Process	OvidSP
EMBASE	OvidSP
Cochrane Database of Systematic Reviews (CDSR)	Cochrane Library/Wiley Interscience
Cochrane Central Register of Controlled Trials (CENTRAL)	Cochrane Library/Wiley Interscience
Database of Abstracts of Reviews of Effects (DARE)	http://www.crd.york.ac.uk/CRDWeb/
Health Technology Assessment Database (HTA)	http://www.crd.york.ac.uk/CRDWeb/
NHS Economic Evaluation Database (EED)	http://www.crd.york.ac.uk/CRDWeb/

Relevant studies were sifted by two reviewers according to the predefined scope, and these studies were then combined with those reported in IPG349. As this approach identified an unmanageable number of studies, a further selection process was employed to identify studies on the basis of methodological quality and size, with randomised controlled trials (RCTs) and observational studies with 200 or more participants selected for full review, and observational studies with 100 or more participants flagged for *ad hoc* inclusion [7]. Systematic reviews and economic studies were also identified.

[Figure 1](#) is a flow diagram of this pragmatic literature review strategy, including the inclusion and exclusion criteria applied to sifting.

Figure 1: Flow chart illustrating the literature review strategy for LAAO.



A brief summary of the results of the literature review is presented in the [results](#) section of this final CtE report on LAAO, with full details available in the standalone literature review document [7].

2.6 RESEARCH DESIGN

The study was a procedural registry designed with a maximum 2 years of follow up. The registry was single armed with no comparator or control arm. Data were collected prospectively in accordance to best practice [8, 9].

As discussed in [Section 3.2](#), there remains some uncertainty regarding the efficacy and safety of LAAO in the management of patients with AF who have absolute or relative contraindications to warfarin and novel oral anticoagulation drugs (NOACs). In particular, there is an issue concerning the generalisability of trial evidence to this population, and how effective and safe the procedure is in real-world practice. To help clarify this uncertainty, NHS England has requested that the answers to 11 clinical and economic questions should be addressed, using data reported by the CtE registry, supported by published studies in the literature. These questions have been revised and adjudicated by NICE (see Table 1).

The EAC performed a pragmatic literature review, which identified the key experimental and observational studies performed to date on LAAO. As the CtE register was non-comparative, data from the literature has been used as a proxy control for the register.

[Table 5](#) summarises the *a priori* intended methods for answering each question [3]. However, due to issues with data quality and reporting of published literature, the original methods were not always possible. These limitations have subsequently been annotated in the table.

The relationship between the registry and published literature in answering the NHS England questions is illustrated in [Figure 2](#). Inference has been made by comparing point estimates and confidence intervals where available. Additionally, in some instances where the registry was not sufficiently robust to answer the questions, published evidence was used to directly answer questions.


Table 5: Methods used to analyse and report CtE registry data.

Question (NICE modified where applicable)	Can it be answered using registry data?	Key registry data required	Type of analysis	Comment
1) Can UK clinical teams reproduce the short and medium success rates for left atrial appendage occlusion reported in existing clinical trials, with equivalent or lower complication rates?	Yes, fully.	Mortality rate. Successful device deployment. Successful occlusion of LAA (LAA sealed). Avoidance of neurological events. Device detachment/embolization. Additional surgery. Readmission. Significant bleed.	Pairwise ('before and after') analysis of registry data. Survival analysis. Comparison with published RCTs and observational studies.	Registry does not provide comparative data so this will be matched with published data. Depending on the goodness of fit, a narrative summary or statistical analysis may be possible. [Update: statistical comparison of registry and published data was not possible].
2) Does left atrial appendage occlusion offer patients a lower risk of stroke or other embolic clinical events in the short and medium term compared with those that would have been predicted on the basis of validated risk scores?	Yes, partly.	Cerebrovascular event. Type of cerebrovascular event. Modified Rankin score (90 days). Overt peripheral embolic event.	Proportion of people having event with confidence intervals. Comparison with expected rate using risk algorithms (CHADS ₂ , CHA ₂ DS ₂ VASc). Survival analysis (Kaplan-Meier).	Outcome events expected to be low, statistical significance unlikely to be reported.
3) Is left atrial appendage occlusion associated with an improved quality of life?	Yes, partly.	Procedural success. Quality of life (EQ-5D-5L).	Pairwise ('before and after') analysis of registry data. Correlation and regression analysis.	Significant aggregate changes in quality of life unlikely. [Update: poor follow up limited meaningful analysis].
4) Are there any longer-term cardiac complications associated with the use of	No, probably not.	Device embolization. LAA sealed.	Proportion of people having event with	Longer-term data collection would be dependent on

Question (NICE modified where applicable)	Can it be answered using registry data?	Key registry data required	Type of analysis	Comment
these devices (e.g. erosion with penetration through the wall of the atrium)?		Thrombus. Significant bleed. Cardiovascular event.	confidence intervals. Survival analysis (Kaplan-Meier).	extension of contracted follow up. [Update: follow up not extended].
5) How many patients with atrial fibrillation with a contra-indication to oral anticoagulants (including previous significant bleed), or who have had a thromboembolic event despite being on oral anticoagulants, are candidates for left atrial appendage occlusion?	Yes, partly.	Decision to treat. Reason for surgery. Plan for treatment. Decision not to offer LAAO.	Proportion with confidence intervals.	Includes patients referred for MDT consideration, not referred patients. [Update: descriptive analysis of indication reported].
6) Which devices are used to undertake LAAO and what are the device-specific efficacy and safety outcomes in CtE funded patients undergoing the procedure?	Yes, partly.	Device implanted/used. Safety and efficacy data.	Subgroup analysis. Comparative survival curves.	Some subgroups may be low in number (real differences may not be statistically observable). Not possible to separate device effects from cardiac anatomy.
7) Is the frequency of complications seen with the intervention clinically acceptable?	Yes, partly.	Key efficacy data (procedural success). Key complication data.	Descriptive statistics on efficacy and complication data. Narrative comparison with published data.	'Clinically acceptable' is a subjective term, will require expert opinion to answer. [Update: comparison with published data, including IPG349 made].
8) Are clinical outcomes from left atrial appendage occlusion associated with particular patient characteristics (clinical or demographic)?	Yes, partly.	Patient characteristics. Efficacy outcomes. Complication outcomes. Mortality.	Subgroup analysis. Bonferroni correction if hypotheses not pre-specified.	Limitations with patient enrolment (power), patient selection and confounding variables (generalisability issues). [Update: low primary event

Question (NICE modified where applicable)	Can it be answered using registry data?	Key registry data required	Type of analysis	Comment
				rate did not allow for meaningful subgroup analysis].
9) What are the full procedural costs of left atrial appendage occlusion to the NHS?	Provides inputs.	Devices used, primary and secondary operator, investigations, length of stay initial admission and procedure duration.	Process costing with separate costs for each stage of the clinical pathway.	Procedural costs will be estimated by combining information from the registry and data from sites, collected using a pro forma.
10) What are the potential cost savings for the NHS through provision of left atrial appendage occlusion for appropriate patients?	Provides inputs.	Patient characteristics. Resource use data for procedure, initial admission and re-admissions. Efficacy outcomes. Complication outcomes.	Cost consequences analysis	Findings from a cost consequences analysis using an economic model will be provided in a separate report to NICE.
11) Is left atrial appendage occlusion cost-effective from the perspective of the NHS?	Provides inputs.	Patient characteristics. Resource use data for procedure, initial admission and re-admissions. Efficacy outcomes. Complication outcomes. Mortality.	Cost consequences analysis	Findings from a cost consequences analysis using an economic model will be provided in a separate report to NICE.

Figure 2: Relationship between NHS England registry clinical data and published evidence identified in the literature review (questions 1 to 8 [Q1 to Q8]).



Section 3: Results

3.1 PRIMARY DATA COLLECTION (CTE DATABASE)

3.1.1 Numbers of Patients Treated at Each Centre

A total of 571 LAAO procedure records were extracted by NICOR on 10th August 2017. Forty six patients did not meet the eligibility criteria, [Appendix 1](#), 14 of which did not include eligible reasons for LAAO treatment, such as patient preference, or primary or secondary prophylaxis regardless of issues with anticoagulation. A total of 525 LAAO procedures were eligible for analysis, which included 44 (8.4%) non-CtE commissioned procedures (i.e. private procedures or those conducted by non-CtE commissioned centres).

Patients were defined as eligible for follow up at each time point if they had concluded their procedure with LAAO device implantation and had a discharge status of alive at last hospital visit. For all patients eligible for follow-up at each time point, information was recorded in 82.4% of cases at 6 weeks, 80.9% at 6 months, 76.1% at 1 year and 70.2% at 2 years (*Supplementary Material – Table 3*).

3.1.2 Summary Statistics of Patient and Procedural Characteristics

Patient demographics and procedural characteristics for the cohort are summarised in [Appendix 2](#) and [Appendix 3](#) respectively. The only statistical difference identified between the whole cohort and those with reported follow-up information was the device used (reflecting patients who did not receive a device [“none”] were not followed up).

3.1.3 Active Surveillance (Evaluation of Coverage)

The data coverage and completeness results for CtE commissioned procedures only, for the 30 LAAO MDS baseline fields (to 30/03/2017) and the 6 specified follow-up fields (to 30/04/2017) are reported in [Table 6](#).

Table 6: Data completeness by CtE-funded provider.

CtE provider	Baseline MDS completeness	Coverage† & completeness‡ at 6 weeks FU	Coverage† & completeness‡ at 6 months FU	Coverage† & completeness‡ at 12 months FU	Coverage† & completeness‡ at 24 months FU
The Newcastle upon Tyne Hospitals NHS Foundation Trust /South Tees Hospitals NHS Foundation Trust*	94%	92.5% (37/40) coverage 89.1% FU data completeness	92.5% (37/40) coverage 89.4% FU data completeness	63.9% (23/36) coverage 91.9% FU data completeness	46.2% (6/13) coverage 54.2% FU data completeness
Liverpool Heart & Chest Hospital NHS Foundation Trust	82%	97.4% (74/76) coverage 83.1% FU data completeness	95.9% (70/73) coverage 83.1% FU data completeness	92.9% (52/56) coverage 81.1% FU data completeness	66.7% (14/21) coverage 78.6% FU data completeness
Leeds Teaching Hospitals NHS Trust	96%	97.1% (33/34) coverage 97.0% FU data completeness	67.7% (21/31) coverage 99.2% FU data completeness	51.9% (14/27) coverage 90.5% FU data completeness	100% (7/7) coverage 73.8% FU data completeness
Oxford University Hospitals NHS Trust	96%	98.3% (58/59) coverage 92.2% FU data completeness	63.8% (37/58) coverage 87.4% FU data completeness	87.3% (48/55) coverage 93.8% FU data completeness	81.2% (26/32) coverage 93.6% FU data completeness
Brighton & Sussex University Hospitals NHS Trust	93%	85.4% (41/48) coverage 65.8% FU data completeness	85.4% (41/48) coverage 72.0% FU data completeness	87.9% (29/33) coverage 71.8% FU data completeness	77.8% (7/9) coverage 71.4% FU data completeness
University Hospital of North Staffordshire NHS Trust	86%	24.1% (13/54) coverage 56.4% FU data completeness	92.6% (50/54) coverage 61.0% FU data completeness	97.3% (36/37) coverage 48.6% FU data completeness	84.6% (11/13) coverage 24.2% FU data completeness
University Hospitals Leicester NHS Trust	82%	81.8% (27/33) coverage 91.3% FU data completeness	93.8% (30/32) coverage 93.9% FU data completeness	91.3% (21/23) coverage 92.0% FU data completeness	100% (8/8) coverage 79.2% FU data completeness
Barts Health NHS Trust & The Heart Hospital*	76%	97.0% (32/33) coverage 93.8% FU data completeness	72.7% (24/33) coverage 97.9% FU data completeness	54.5% (12/22) coverage 97.2% FU data completeness	0% (0/1) coverage 0% FU data completeness
Kings College Hospital NHS Foundation Trust	86%	84.2% (16/19) coverage 81.3% FU data completeness	78.9% (15/19) coverage 83.3% FU data completeness	76.9% (10/13) coverage 83.3% FU data completeness	40% (2/5) coverage 16.7% FU data completeness
Guy's and St Thomas' NHS Foundation Trust	98%	70% (21/30) coverage 71.5% FU data completeness	78.6% (22/28) coverage 75.8% FU data completeness	58.3% (14/24) coverage 50% FU data completeness	50% (2/4) coverage 33.3% FU data completeness
Total	89%	428/431 (99.3%) with device implanted, discharged alive and	418/423 (98.8%) with device implanted, still alive at 6 weeks FU and	328/419 (78.3%) with device implanted, still alive at 6 months FU and	115/411 (28.0%) with device implanted, still alive at 12 months FU and reaching 24

CtE provider	Baseline MDS completeness	Coverage† & completeness‡ at 6 weeks FU	Coverage† & completeness‡ at 6 months FU	Coverage† & completeness‡ at 12 months FU	Coverage† & completeness‡ at 24 months FU
		reaching 6 weeks since procedure date. 354/428 (82.7%) with some degree of FU data. Completeness of FU MDS (versus expected) = 84.2%.	reaching 6 months since procedure date. 342/418 (81.8%) with some degree of FU data. Completeness of FU MDS (versus expected) = 81.9%.	reaching 12 months since procedure date. 259/328 (79.0%) with some degree of FU data. Completeness of FU MDS (versus expected) = 79.4%.	months since procedure date. 85/115 (73.9%) with some degree of FU data. Completeness of FU MDS (versus expected) = 70.4%.
<p>FU Coverage† = Actual No. of LAAO procedures with some degree of FU data entered / No. of LAAO procedures eligible for FU for the stated period (%).</p> <p>NB FU Coverage can only be calculated for cases with a procedure date entered. This is the case for 481/492 (97.8%) of LAAO cases in the registry, to 10/08/2017.</p> <p>FU Completeness‡ = Average completeness of the 6 specified LAAO MDS-FU data fields (%).</p> <p>*CtE providers named in bold font in the table are separate NHS Trusts operating in partnership as a single contracted CtE provider with NHS England for cardiac CtE.</p>					

3.1.4 Outcomes

a. Clinical

A total of 509 procedures (97.0%) recorded both admission and discharge dates, showing a median length of stay of 1 overnight stay (inter-quartile range [IQR] 1 to 1, range 0 to 52 overnight stays). A total of 114 procedures (22.4%) resulted in an extended length of stay (2 or more nights in hospital). Device implantation was achieved in 93.6% of all attempted LAAO procedures, in-hospital major complication occurred in 5.5% and in-hospital minor complications occurred in 4.6% of procedures. Four hundred and forty six procedures (89.0%) were considered a procedural success (i.e. device implanted and no major complications). Frequencies of in-hospital outcomes for all eligible LAAO patients, and post-discharge outcomes for all eligible LAAO patients with a device implanted are described in [Appendix 4](#).

Detailed results from univariate analyses for in-hospital technical success (device implanted), in-hospital major complication and in-hospital minor complication are described in the *Supplementary Material – Tables 4-6* respectively. No covariates were significantly associated with these outcomes.

Crude incidence rates of adverse events are described in [Appendix 5](#). Of the 25 reported deaths, 5 occurred in hospital, and 23 had a recorded cause of death, whereas the remaining 2 had entered a non-specific record or stated cause of death to be advised:

- 4 attributed to sepsis (1 of these urinary, 1 with chest infection and 1 query staphylococcal septicaemia);
- 4 attributed to cancer (1 cancer of the caecum with secondary anaemia, 1 oesophageal cancer, 1 metastatic bowel cancer, 1 metastatic lung cancer);
- 3 strokes (2 of these ischaemic strokes and the other not related to LAA [assumed haemorrhagic origin]);
- 2 attributed to intracranial haemorrhage;
- 2 attributed to pneumonia (1 with lung fibrosis);
- 2 attributed to end stage renal failure;
- 1 each attributed to heart failure; air embolism with cerebral oedema; cardiac tamponade; a gastric mass not associated with LAA; chest infection; complications of diabetes.

Nineteen neurological events were reported: 11 ischaemic (one of which was recorded as CVA/RIND), 4 haemorrhagic, and 4 undetermined. The crude event rate for ischaemic stroke (using n=10 events) was 2.6 (95% CI 1.3 to 4.8) events per 100 person-years (PY) follow up.

Kaplan-Meier curves for time to death, neurological events and death or neurological event are shown in [Appendix 6](#). No significant association was found between death or neurological events and device manufacturer ([Appendix 7](#)).

Use of medications over time is described in the *Supplementary Material – Table 7*.

In reporting changes in quality of life, one can only include individuals who provided data pre-procedure and at specified later time periods. This is to ensure one is comparing the EQ-5D scores of the same individuals over time. The mean utility value pre-procedure was 0.78, which changed to:

- 0.82 at 6 weeks (n= 131);
- 0.83 at 6 months (n = 144);
- 0.82 at 12 months (n = 101);
- 0.78 at 24 months (n = 32).

However, none of these changes reached statistical significance.

No significant changes in individual quality of life (EQ-5D) components or utility scores were observed over time. The domain registering the greatest benefit from the procedure was reduction in anxiety and depression (*Supplementary Material – Table 8*).

b. Cost / resource (include model here if appropriate)

The overall quality of responses to the LAAO CtE Excel[®] costing template was poor, but there was 1 well-completed response. NY EAC synthesised the responses to create a list of the resources required at each stage of pathway. In February 2017, Dr Mark de Belder reviewed the template. Following subsequent changes in light of his comments and informed by several more responses from centres, NY EAC updated the template and included cost information. Unit costs were taken from published national datasets (primarily NHS Reference Costs [10] and PSSRU [11]). The NHS Supply Chain provided costs for the device as ‘Commercial in confidence’ and hence must not be disclosed beyond NICE staff and clinical leads in first instance. Such data are identified in yellow in this report and [Appendix 8](#). NHS Supply Chain price includes overheads of 3% for its internal costs. A further 15% has been added to the NHS Supply Chain price for NHS procurement and stores related costs plus property, finance and administration related overheads.

At this stage we also included results from the analyses of registry data from the centres for as many parameters as possible. These included number and type of device implanted, type of imaging conducted at each stage in the pathway, procedure duration, primary and secondary operator and length of stay. The updated templates were presented at a meeting of the 3 clinical leads in May 2017. Comments from that meeting informed the final pathway and costings.

The 2 rounds of clinical validation were judged essential to ensure the resulting costs have good internal and external validity and thus should generalise to settings across NHS England.

The resultant estimated central cost and high and low cost scenarios for an LAAO procedure conducted in NHS England are shown in [Table 7](#).

Table 7: Central cost and range of costs for an LAAO procedure.

Pathway stage	Central cost	Low cost	High cost
Pre-operative assessment	£792	£413	£1,000
Peri-operative procedure	£8,933	£8,162	£9,668
Post-operative management	£1,864	£913	£2,666
Total	£11,589	£9,488	£13,334

[Table 8](#) analyses the estimated costs by component and stage for the central case. The device accounts for █% of the cost, with investigations forming the second largest cost component (█%), staff comprise █%, consumables and length of stay are each 5%, theatre use contributes about 4% to the cost, with outpatient follow-up being 2%.

Table 8: Estimated costs by component by stage for central case.

	Pre-op	Peri-op	Post-op	Total	% of Total
Device		█		█	█
Investigation	£634	█	£1,106	█	█
Staff	£142	█		█	█
Consumables	£16	£598		£614	5%
Length of stay			£567	£567	5%
Theatre		£422		£422	4%
Out-patient			£191	£191	2%
Total	£792	£8,933	£1,864	£11,589	100%

A full summary of all resources and unit costs is provided in [Appendix 8](#). This also describes the assumptions underpinning the sensitivity analyses.

c. Patient experience


Pre-procedure, EQ-5D values were available for 272 patients. At 6 weeks, 131 paired scores were available and these showed a mean gain in utility of 0.02, with 31% of patients reporting improved quality of life, 45% no change and 24% a deterioration. At 6 months, paired data for 144 patients were available. These showed a similar marginal improvement in the utility score of 0.01, with 38% of patients reporting improved quality of life, 36% no change and 26% a deterioration. The mean baseline value was 0.80 ± 0.20 ; however, the median value of 0.82 was adopted as a measure of central tendency.

Full EQ-5D results are presented in *Supplementary Material - Table 8*.

3.2 SECONDARY DATA COLLECTION (LITERATURE REVIEW)

The CtE LAAO literature search retrieved 1,165 potentially relevant articles. Abstracts from these articles were independently assessed for relevance by two EAC researchers. Of these, 961 were excluded immediately after screening as being not relevant to the scope. Of the remaining 211 records, 181 were excluded for various reasons, including 16 studies that were identified as systematic reviews and/or meta-analyses and 15 studies that reported on economic or QoL outcomes. These were used in the economic evaluation. The most prevalent reason for exclusion at the sifting stage was because of study size (58 studies reported on less than 100 patients). The process of sifting using PRISMA methodology (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) [12] is illustrated in [Figure 3](#) below.

Figure 3: PRISMA schematic of literature search for clinical evidence.



The CtE LAAO literature search identified 30 publications in scope. Of these, 17 publications pertaining to 2 RCTs and 3 observational studies were selected for focussed review. The remaining publications were identified as in scope, but were not analysed further, mainly due to study size (more than 100 but less than 200 participants). One study from [NICE IPG349](#) was selected which was the seminal paper of one of the RCTs; the other studies were excluded on the basis that they described a technology not now available to the NHS or reported sample sizes below the threshold specified in the scope (i.e. less than 100 patients). In addition to the primary studies, 16 secondary studies (systematic reviews and/or meta-analyses) were identified; 4 of which were selected for interim analysis. Fifteen potentially informative economic studies were flagged.

The two RCTs identified were the PROTECT AF (n = 707) [13] and PREVAIL trials (n = 407) [14]. Both these trials, performed by the same research group, investigated the use of the WATCHMAN device in patients *without* a contraindication to warfarin. Patients were randomised in a 2:1 ratio to receive WATCHMAN (combined with warfarin for minimum 45 days) or chronic treatment with warfarin. The primary outcomes were composites related to efficacy (longer term prevention of ischaemic events) and safety (procedural adverse events and excess bleeding). The EAC appraised these studies and found they showed good methodological quality, but lacked generalisability because of the use of warfarin in both arms. In summary, the results of the PROTECT AF trial demonstrated non-inferiority compared with warfarin in primary efficacy and safety outcomes at a follow up of up to 3.8 years; however, the rate of procedure-related adverse effects was a concern, with 4.8% of patients suffering serious pericardial effusion. The PREVAIL trial did not demonstrate non-inferiority in its primary efficacy outcomes, which was attributed to an unusually low event rate in the warfarin arm. However, this study reported a reduction in procedural adverse events compared with the PROTECT AF trial.

The observational studies were single-armed and therefore of limited methodological quality. The EWOLUTION registry (2016) [15] investigated the use of the WATCHMAN device (n = 1014) but was limited to peri-procedural outcomes (mainly 30 days or less). A one-year analysis of the EWOLUTION registry [16], published after the literature search cut-off date, was identified by stakeholders during the consultation process. As this study had been previously appraised [7], and the longer-term results were relevant to those of the registry, this analysis was accepted for this report.

The study by Betts *et al.* (2016) [17] was a retrospective audit of routinely collected data from patients (n = 371) undergoing LAAO (any device, principally WATCHMAN or AMPLATZER Cardiac Plug [ACP]). It reported outcomes with a mean follow up of 24.7 months. The ACP registry (n = 1053) [18] investigated this device with a mean follow up of 13 months. Whilst these trials lacked internal validity and did not provide comparative data, they reflected real-life practice (used mainly in patients ineligible for warfarin), with the study by Betts *et al.* in particular being highly generalisable, being set in the UK NHS and enrolling patients with similar indications to the registry. Procedural safety was comparable to the RCTs. The EWOLUTION registry, ACP registry, and Betts study all reported superior efficacy outcomes than would be expected according to standardised risk scores.

Results from the four systematic reviews and meta-analyses provided aggregate data of higher precision than individual studies (but were limited in generalisability because of the heterogeneous nature of the contributory studies) [7]. An individual meta-analysis [19] of the 2 RCTs showed broad equivalence of WATCHMAN and warfarin in overall stroke rates, but reported superiority in the prevention of haemorrhagic stroke and cardiovascular death. This was largely supported by a network analysis [20]. Two systematic reviews and meta-analyses of observational data provided further estimates of efficacy and adverse events [21, 22].

The literature review, supplemented by an update in May 2017, identified 15 economic studies that met the inclusion criteria. Evidence from eight economic studies reported that the WATCHMAN LAAO device was cost-effective in certain high cost settings, particularly in North America, compared with patients managed on NOACs or warfarin. Costs in the LAAO arm were initially higher but, over time, savings from fewer strokes result in lower total costs and higher quality-adjusted life years (QALYs) compared with anticoagulants. Financial break-even was around 8 to 10 years depending on the comparator, being shorter with NOACs than warfarin. One study, based on a subset of 547 patients in the PROTECT-AF RCT, reported that at 12 months, patients receiving LAAO had an increase in quality of life compared with baseline, whilst those treated with warfarin experienced a decline [23].

Evidence in the population contraindicated to NOACs or warfarin was limited to 6 studies, of which one generalised to the UK setting [24]. This study used registry data and reported LAAO was cost saving in the contraindicated population with the benefit being higher than for the wider population. However, further evaluations are required to confirm these findings, particularly since it was not based on direct randomised evidence. It is likely patient selection is important and cost-effectiveness will be dependent on the risk of stroke and bleeding. Further evaluations are also required on the relative efficacy and costs of alternative devices.

Further details are available in the standalone literature review document by Willits *et al.* (November 2016) [7].

3.3 NHS ENGLAND QUESTIONS

The aims of the CtE registry were to provide data on the safety, efficacy and costs of LAAO in the real-world NHS setting and specifically to answer 11 pragmatic questions concerning these issues. In this section, the findings from the CtE registry are used to answer these questions and are presented in the context of published studies in other populations. [Table 9](#) summarises some key characteristics that illustrate the risk profile of patients undergoing LAAO in the CtE programme, key clinical trials and large observational studies.

Table 9: Summary of patient characteristics in the CtE registry and published literature.

Study	Age in years (SD)	CHADS ₂ or CHA ₂ DS ₂ -VASc score	HAS-BLED score Mean (SD) Median [Range]	Pre-procedure medications	
CtE registry	Mean: 74.5 (8) Median: 75 [70, 80]	<u>CHADS₂</u> Mean 2.9 (1.3 SD) Median 3 (IQR 2 to 4) <u>CHA₂DS₂-VASc</u> Mean 4.3 (1.5 SD) Median 4 (IQR 3 to 5)	Mean: 3.7 (1.1 SD) Median: 4 (IQR 3 to 5)	Antiplatelet only = 32.0% Anticoagulant only = 18.2% Other or none = 49.8%	
RCTs*	PROTECT-AF	<u>LAO:</u> Mean 71.7, (8.8 SD, range, 46.0 to 95.0) <u>Control:</u> 72.7 (9.2 SD, range 41.0 to 95.0)	Mean CHADS ₂ = 2.2 (SD N/R)	N/R (likely to be low as patients eligible for warfarin)	100% patients on warfarin.
	PREVAIL	<u>LAO:</u> 74.0, (7.4 SD, range 50.0 to 94.0) <u>Control:</u> 74.9 (7.2 SD, range 53.0 to 90.0)	Mean CHADS ₂ = 2.6 (SD N/R)	N/R (likely to be low as patients eligible for warfarin)	100% patients on warfarin.
Observational studies	UK registry (Betts)	72.9 (8.26)	<u>CHADS₂</u> Mean: 2.63 (1.24) <u>CHA₂DS₂-VASc</u> Mean: 4.22 (1.56)	Mean: 3.34 (1.17)	Not stated but most contraindicated to warfarin. 61% discharged on antiplatelet treatment, 39% on a regimen including anticoagulation.
	EWOLUTION registry	73 (9)	<u>CHADS₂</u> Median: 3 (IQR N/R) <u>CHA₂DS₂-VASc</u> Mean: 4.5 (1.6) Median: 4	Mean: 2.32 Median: 2	N/R
	ACP registry	75 (8)	<u>CHADS₂</u> Mean: 2.8 (1.3 SD) <u>CHA₂DS₂-VASc</u> Mean: 4.5 (1.6 SD)	Mean: 3.1 (1.2) Median: 3	N/R Most patients discharged on dual antiplatelet therapy.
	CAP registry*	74 (8)	<u>CHADS₂</u>	N/R	100% patients

			Mean 2.4 (1.2 SD)		on warfarin.
	ASAP registry	72.5 (7.4)	CHADS ₂ Mean: 2.8 (1.2 SD) CHA ₂ DS ₂ -VASc Mean: 4.4 (1.7 SD)	N/R	Patients contraindicated to warfarin.
Abbreviations. IQR – inter-quartile range; N/R – not reported; SD – standard deviation. * The RCTs and CAP registry used LAAO (WATCHMAN) combined with 90 days oral anticoagulation with warfarin as the intervention. Most patients in the observational studies did not take oral anticoagulation.					

Qualitative analysis of the baseline characteristics of the study populations show that, in general, patients enrolled into the RCTs were eligible to receive warfarin and indeed received this as part of the intervention (for 45 days post-procedure). Additionally, patients in the PROTECT-AF and PREVAIL trials had lower CHADS₂ risk scores than those recruited for the CtE registry. This means that published trial participants were at reduced risk of ischaemic stroke compared to the CtE registry, and therefore it would be expected trial patients would have superior outcomes in this regard, all other things being equal. In contrast, patients enrolled into the observational studies tended to more closely reflect the patients in the CtE registry in terms of ischaemic stroke risk. Crucially, patients in the selected observational studies were relatively or absolutely contraindicated to oral anticoagulation and were therefore a closer match to patients in the CtE registry.

3.3.1 Question One

“Can UK clinical teams reproduce the short and medium success rates for left atrial appendage occlusion reported in existing clinical trials, with equivalent or lower complication rates?”

For the purposes of answering this question, “short [term] success rates” has been defined as technical and procedural success of device implantation in hospital. “Medium [term]” success rates pertains to the prevention of ischaemic neurological events and death associated with LAAO implantation as measured by the registry. As longer term follow up in the registry was limited (see [Section 4.3](#)), data were combined over all follow up periods and presented as annualised event rates (events per 100 person-years [PY]).

Short term success

The technical success of LAAO was defined as the proportion of devices successfully implanted in patients where it was attempted. The reported rate by participating centres was 93.6% (95% CI 91.1% to 95.6%). Procedural success was defined as technical success in the absence of major complications and was reported as 89.0% (95% CI 86.0% to 91.6%). Thus, approximately one in ten procedures carried out was unsuccessful. In those in whom a device was implanted, 434/469 (92.5%) had no leak, 32/469 (6.8%) had a minor leak, 1/469 had a moderate leak (0.2%) and 2/469 (0.4%) had a major leak ([Appendix 4](#)).

Clinical failure was reported in 9.1% of patients (95% CI 6.6% to 12.2%) following TOE examination at follow up. The reasons for clinical failure were: the device was not found *in situ* in 5.9% of patients and in a further 1.6% of patients, the LAA was found not to be

sealed, having a large leak (≥ 3 mm). Four patients (0.8%) were classified as a clinical failure because they suffered a neurological event before hospital discharge.

The short term success rate of LAAO performed through CtE was compared with published data from trials and observational studies ([Table 10](#)). Direct comparisons are confounded due to differences in definitions of technical or procedural success, which were not always explicitly defined in the literature. However, it can be seen that short-term success rates are largely consistent with the published data. The PROTECT-AF trial [13] reported a success rate of 91%, which increased to 95% for data reported by the PREVAIL trial [14], an improvement that was partly attributed to the learning curve effect (as both studies were conducted by the same clinical teams). It is likely that the RCT data from this procedural outcome are generalisable to the trial registry, although it was restricted to the WATCHMAN device only.

The UK registry by Betts *et al.* (2016) [17] provided the most generalisable data, which are consistent with the CtE success rates. Data from the other large observational studies [15, 18] reported numerically higher implantation success rates, but appear to be within the confidence intervals of the present CtE study. Two other registries of note by the Holmes group of researchers (WATCHMAN), the Continued Access Protocol (CAP) registry [25] and ASA Plavix Feasibility Study With WATCHMAN Left Atrial Appendage Closure Technology (ASAP) registry [26], reported numerically higher success rates but still within the upper confidence limit of the CtE registry.

Table 10: Summary of technical and procedural success of CtE patients and published data.

Study		Technical and procedural success (95% CI)	Definition*
CtE registry		Technical success: 93.6% (91.1% to 95.6%)	Device successfully implanted.
		Technical success with no leak: 86.6% (83.3% to 89.5%)	
		Procedural success: 89.0% (86.0% to 91.6%)	Device implanted in absence of major complications.
RCTs	PROTECT-AF	91%	Successful implant of those attempted.
	PREVAIL	95.1%	Successful implant of those attempted.
Observational studies	UK registry	92.5%	Defined as “the percentage of successful device implants among patients in whom a device was opened and deployment was attempted”
	EWOLUTION registry	Successful 98.5% Complete seal 91.4%	
	ACP registry	97.3%	Defined as “successful implantation of the ACP in the left atrial appendage”.
	CAP registry	95.0%	Successful implant of those attempted.
	ASAP registry	94.7%	Successful implant of those attempted.

* Definitions of procedural or technical success not always reported and not consistent.

Medium term success

The primary purpose of LAAO is to prevent ischaemic stroke in high risk populations (people with AF absolutely or relatively contraindicated to warfarin and NOACs). The registry recorded neurological event rates as a primary efficacy outcome, and, in addition, all-cause mortality as a proxy efficacy outcome. These outcomes were also combined (death or neurological event outcome) which more closely represents the primary outcomes used in the non-inferiority RCTs.

Twenty-five patients died during the CtE registry study period (4.8%), and additionally 19 had neurological events (3.6%). As some neurological events were fatal, this equated to a combined total of 39 major complication events (7.4%). During an aggregated total of almost 400 person-years of follow up, the annualised event rates were 6.2 per 100 PY for death, 5.0 per 100 PY for all neurological events, and 9.8 per 100 PY for the combined outcome ([Appendix 5](#)). There were 10 ischaemic events, giving a rate of 2.6 (95% CI 1.3 to 4.8) per 100 patient years.

The efficacy outcomes and those reported in the published literature, principally the PROTECT-AF [13] and PREVAIL trials [14], are shown in [Table 11](#). It is important to acknowledge that the studies, and the CtE registry, are not directly comparable because of differences in the sample population ([Table 9](#)) and definitions of outcome measures.

The CtE registry reported a higher incidence of death, neurological events, and composite of these, than the RCTs. As the lower confidence intervals reported in the registry did not overlap with the upper confidence intervals reported in the RCTs, this suggests a real, significant difference in event rates [27]. Furthermore, the difference in point estimates is large, indicating the difference may be clinically important. It is important to consider these results within the context that there were differences in definitions of events (primary outcome, stroke, neurological event, or death), and that the populations were different ([Table 9](#)). However, the event rates are also high compared with those reported in the some of the other observational studies [25, 26], including the UK registry by Betts *et al.* (2016) [17].

Table 11: Summary of medium term efficacy outcomes (death and neurological event) from CtE and eligible studies.

Study		Primary outcome ¹	Death ²	Neurological event/ stroke
		Reported in events per 100 person-years follow up (with 95% CI where applicable).		
CtE registry		9.8 (7.0 to 13.4)	6.2 (4.0 to 9.2)	5.0 (3.0 to 7.8)
RCTs	PROTECT-AF ³	3.0 (1.9 to 4.5)	1.0 (0.6 to 1.5)	1.5 (1.0 to 2.2)
	PREVAIL ⁴	5.2	2.6	2.2
Observational studies	UK registry (Betts)	N/A	1.8	0.9
	EWOLUTION registry	N/A	6.9	1.1 ⁵
	ACP registry	N/A	N/A	2.3 ⁶
	ASAP registry	4.6	5.0	2.3

Abbreviations. N/A: Not available.

1. Primary outcome of studies refers to composites of stroke, systemic embolism, and death, which differ slightly between studies. For the CtE registry, this composite consisted of death (by any cause) or any neurological event.
2. For the CtE registry, all deaths were included. For some studies, death was restricted to cardiovascular or unexplained death.
3. Data reported from seminal study (mean follow up 18 months) [13]. Primary event rate in the extended follow up study (mean 3.8 years) [28] was 2.3 (95% CI 1.7 to 3.2) per 100 person-years.
4. Event rate estimated by EAC from reported data (using raw event rates and median follow up).
5. Ischaemic stroke. Combined rate for stroke, TIA, and systemic thromboembolism was 1.5 per 100 person-years.
6. Annualised rate reported (%), equivalent to events per 100 person-years.

The individual meta-analysis by Holmes *et al.* (2015) [19], which combined data from the PROTECT-AF and PREVAIL RCTs with the CAP and CAP2 registries (the CAP2 registry being an unpublished continued access extension of the PREVAIL trial), reported a rate of all cause stroke or systemic embolism of 1.75 events per 100 PY. The rate of cardiovascular or unexplained death was reported as 1.1 per 100 PY. A stroke event rate of 1.8 (95% CI 0.7 to 2.5) per 100 PY was reported in the meta-analysis by Xu *et al.* (2016) [22] when studies reporting outcomes of 12 months or less were pooled. The rate was lower (1.2 [95% CI 0.8 to 1.5]) when studies reporting stroke rate from 12 months or longer were pooled.

There are several possible explanations for the ostensibly higher rates of neurological events observed in the CtE registry compared with the literature. Firstly, it may be that the outcomes being compared are not equivalent due to differences in terminology and definitions (that is, it is an “apples and pears” comparison). In the LAAO CtE database, in-hospital neurological events could be recorded by mechanism (ischaemic / haemorrhagic /

undetermined / other) and type of event (CVA/RIND, TIA, other). However, at follow-up, only the mechanism of event was recorded.

Secondly, the rate of neurological events should be considered in the context of time to event analysis and the nature and severity of the events. Time to event analysis of neurological events and death are illustrated by Kaplan-Meier curves in [Appendix 6](#). Of the 19 neurological events, four occurred in hospital. One was haemorrhagic, two were undetermined mechanism and the mechanism of the fourth was not recorded, although the type was recorded as a CVA/RIND. This is in contrast to the data from the RCTs and associated registries which reported no neurological events directly associated with the procedure [13-15, 18]. However, for three of these four CtE in-hospital events, the modified Rankin Scale score at 90 days post-event was recorded, showing that one patient had no symptoms (Rankin score 0) and the other two had some symptoms, but no significant disability (Rankin score 1). The fourth in-hospital event was an air embolism which resulted in the patient's death. There were a further 15 neurological events in the CtE patients post-discharge from hospital, which consisted of ten ischaemic events, three haemorrhagic events, and two undetermined events. Reversible neurological events such as TIA do not appear to have been reported in the published RCTs [13, 14]. Following hospital discharge, at least ten of the recorded events could be considered to be associated with failure of device efficacy (that is, they were ischaemic events that had not been prevented), although a causal link was not demonstrated.

Thirdly, the population receiving LAO is likely to be different in the CtE registry compared with the population in the published literature, particularly the RCTs. Patients from the registry had a median CHADS₂ score of 3, and a median CHA₂DS₂-VASc score of 4, which was higher than patients enrolled in the PROTECT-AF and PREVAIL trials (mean CHADS₂ scores of 2.2 and 2.6 respectively) (see Table 9). The relationship of CtE data with CHADS₂ and CHA₂DS₂-VASc scores are summarised in [Question Two](#).

Half (50%) of the patients in the registry had suffered a previous cardiovascular accident (CVA), compared with 18% in the PROTECT-AF and 28% in the PREVAIL trial. This means patients in the registry were at higher risk of ischaemic stroke than those in the trials. Additionally, the patients in the registry were at least relatively contraindicated for treatment with warfarin and did not take oral anticoagulation as part of their intervention, which further limits generalisability of the evidence (see full literature review [7] for discussion). Patients in the registry had a relatively high risk of bleeding as measured by HAS-BLED score.

In-hospital complication rates

The CtE registry recorded detailed information about in-hospital complications and patient coverage for these outcomes was high. Overall, the composite rate of in-hospital complications described as major was 5.5% (95% CI 3.7% to 7.8%). Although the definition of in-hospital "major complication" differs slightly between studies, this figure from CtE is consistent with those published in the literature, which ranged from 2.2% (PREVAIL trial [14]) to 8.7% in the ASAP registry [26].

Breaking down the complications that contributed to the major complication composite outcome, there was no evidence that complications in CtE were better, worse, or inconsistent with those published in the literature. No in-hospital deaths were reported in the RCTs, but the CtE rate of 1.0% (95% CI 0.3% to 2.2%) was consistent with three large published registry studies identified [15, 17, 18]. The rate of pericardial effusion requiring intervention (2.1%) was lower than that reported in the PROTECT-AF trial (4.8%) [13], but consistent with the other studies identified. The proportion of CtE patients experiencing device embolisation at 0.8% (95% 0.2% to 1.9%) was also consistent with other studies. Other major in-hospital complications were generally poorly reported in the literature, making comparisons difficult. The frequency of major in-hospital complications from the registry and published literature is reported in [Table 12](#).

Table 12: Summary of major in-hospital complications for CtE and reported in the literature

Outcome	CtE registry	RCTs*		Observational studies				
		PROTECT-AF	PREVAIL	UK registry	EWOLUTION	ACP registry	CAP registry	ASAP registry
Major complication	5.5% (3.7 to 7.8%)	NR**	2.2%	3.5%	3.6 (95% CI 2.5 to 4.9%)*	5.0%	3.7%	8.7%
Death	1.0% (0.3 to 2.2%)	0%	0%	0.25%	0.7%	0.8%	NR	0%
Neurological event	0.8% (0.2 to 1.9%)	1.1%	NR**	1.35%	0.1%	0.9%	0%	0.7%
Pericardial effusion (requiring intervention)	2.1% (1.1 to 3.7%)	4.8%	0.4%†	0.81%	0.3%	1.2%	2.2%	1.3%
Embolisation	0.8% (0.2 to 1.9%)	0.6%	0.7%	1.35%	0.02%	0.8%	NR	1.3%
Surgical intervention	1.9% (0.9 to 3.5%)	1.9%	NR	0.25%	NR	NR	NR	0.7%
Major vascular injury	1.0% (0.3 to 2.2%)	NR	NR	NR	NR	0.4%	NR	0.7%
Major bleed	1.9% (0.9 to 3.5%)	NR**	0.4%	0.54%	1.0%	1.2%	NR	1.3%
MI	0.4% (0.0 to 1.4%)	NR	NR	NR	NR	NR	NR	NR
AKI (Stage 2 or 3)	0.6% (0.1 to 1.7%)	NR	NR	NR	NR	NR	NR	NR
Endocarditis	0.4% (0.0 to 1.4%)	NR	NR	NR	NR	NR	NR	NR

Abbreviations. NR: Not reported.
* Intervention arm of RCT reported (WATCHMAN plus 45 days warfarin).
** Procedural and post-procedural data not disaggregated.
*** Device or procedure related adverse event within 30 days of procedure.
† Requiring surgical pericardiocentesis.

Two of the most common adverse events associated with LAAO, major bleeding or haemorrhagic events, have been summarised in two meta-analyses. Wei *et al.* (2016) [21] reported a low frequency of haemorrhagic complications of about 1% (0.01 [95% CI: 0.00 to 0.01]) compared with a rate of 2.6% (95% CI, 1.5% to 3.6%) reported by Xu *et al.* (2016) [22]. The reported rate of pericardial effusion and/or tamponade was similar for both studies and consistent with the other studies, with rates of around 2% (0.02 [95% CI 0.02 to 0.03]) and 2.5% (95% CI 1.8% to 3.2%) respectively.

The incidence of minor in-hospital complications found in the CtE registry has been reported in [Appendix 4](#). An incidence of 4.6% (95% CI 3.0 to 6.7%) reported from the CtE registry was numerically lower than the incidence of more serious adverse events. This compares with a rate of 2.2% reported in the UK registry by Betts (2016) [17] and 1.5% in the ACP registry [18]; however, these studies used different criteria in their definition. Numbers of events were too low in the CtE registry to provide a meaningful analysis of individual event type. It is possible that minor complications were underreported.

Conclusion

Data reported from the CtE registry suggest the rates of technical and procedural success (short-term efficacy) achieved by hospitals participating in the CtE programme are consistent with those published in the literature. The CtE population was at higher risk of stroke than reported in the previous studies, which may have been reflected by the annualised rate of neurological events, which was higher than had been reported in RCTs or other observational studies. The death rate, although high, was consistent with the EWOLUTION registry [16], which had a similarly-risked population ([Table 9](#)). However, overall, the EAC considered that due to the incomplete follow up data and differences in population and intervention of registry data compared to trial data, clinical equivalence was inconclusive, and it is not possible to determine whether the medium-term efficacy rate is equivalent to other studies or not. The in-hospital major complication rate of LAAO of 5.5% reported in the CtE registry is consistent with that reported in the literature.

3.3.2 Question Two


“Does left atrial appendage occlusion offer patients a lower risk of stroke or other embolic clinical events in the short and medium term compared with those that would have been predicted on the basis of validated risk scores?”

The best known and most extensively used, validated risk scores for embolic stroke risk are the CHADS₂ and CHA₂DS₂-VASc scoring systems. The CHADS₂ system was developed from the amalgamation of two earlier algorithms developed from the Atrial Fibrillation Investigators (AFI) pooled data and data from the Stroke Prevention and Atrial Fibrillation (SPAF) investigators, and was validated in 2001 against a US database of Medicare insurance claimants (n = 2121 PY) [29]. This system has since been largely superseded by the CHA₂DS₂-VASc scoring system, which has been validated in a European cohort of patients (n = 1084 subjects) [30]. This has incrementally improved the CHADS₂ system by increasing the specificity of age and introducing gender and presence of vascular disease as additional risk factors. The CHA₂DS₂-VASc algorithm is thought to be a superior predictor of

thromboembolic risk [31] and has been incorporated into current NICE clinical guidelines on AF (CG180) [32].

All patients were assessed for their risk of stroke using the CHADS₂ and CHA₂DS₂-VASc scores, with patients only being eligible for the CtE registry if they have a CHA₂DS₂-VASc of 2 or more (and contraindications to oral anticoagulation) [4]. The median CHADS₂ score of the registry cohort was 3, with a range of 0 to 6. The median CHA₂DS₂-VASc score was 4, ranging from 0 to 9 (the lower range indicating some patients were enrolled who were not technically eligible). The distribution of CHA₂DS₂-VASc scores is illustrated in [Figure 4](#).

Figure 4: Distribution of CHA₂DS₂-VASc score illustrated by histogram and box and whisker plot (n = 525)



The purpose of the risk scores is to predict the risk of an embolic event causing an ischaemic stroke or peripheral embolism in patients not receiving oral anticoagulation. There were ten ischaemic events and no peripheral emboli recorded by the CtE registry. This equates to a crude rate of 2.6 (95% CI 1.3 to 4.8) events per 100 PY. Although comparative statistical analysis is not possible, this result would be consistent with LAO performing better for this outcome than historical controls not receiving anticoagulation (see [Table 13](#)).

Table 13: Incidence of ischaemic events and peripheral embolism in CtE and expected rates from the literature (events per 100 PY).

Risk algorithm system	Risk score (median score from registry)	Expected incidence of thromboembolic event (% per year)	Actual incidence of thromboembolic event from registry (events per 100 PY)
CHADS ₂ [29]	3	5.9 (95% CI 4.6% to 7.3%)*	2.6 (95% CI 1.3 to 4.8)
CHA ₂ DS ₂ -VASc [30]	4	4.0**	
CHA ₂ DS ₂ -VASc [33]	4	At 1 year: 9.27 (95% CI 8.71% to 9.86%)* At 5 years: 6.69 (95% CI 6.41% to 6.99%)* At 10 years: 6.46 (95% CI 6.20% to 9.74%)*	
<p>*Adjusted rate from exponential survival model, assuming aspirin was not taken. **Adjusted rate, assuming warfarin provides a 64% reduction in thromboembolic risk. *** Adjusted rate (excluding patients receiving NOACs) estimates with 1, 5, and 10 years follow up. Note: EAC has not appraised the source data of this study (from Danish national registry data).</p>			

All of the selected observational studies made comparisons with expected thromboembolic events from risk scores. The UK registry by Betts *et al.* (2016) [17] reported that the use of LAO was associated with a relative risk reduction (RRR) of events of 90.1% and 87.2% compared with expected events using CHADS₂ and CHA₂DS₂-VASc scores respectively. The ACP registry by Tzikas *et al.* (2016) [18] reported an estimated 59% reduction in stroke rate compared with expected values using the CHA₂DS₂-VASc score. The update of the EWOLUTION study [16] reported a reduced relative risk of 84% in ischaemic strokes compared with expected values from CHA₂DS₂-VASc predictions.

Conclusion

Data from the CtE registry are consistent with LAO conferring a substantial reduction in embolic events as would be expected using CHADS₂ or CHA₂DS₂-VASc prediction scores.

3.3.3 Question Three

“Is left atrial appendage occlusion associated with an improved quality of life?”

Quality of life (QoL) was measured in the registry at baseline and at follow up (6 weeks, 6 months, 1 year and 2 years) using the EuroQol system (EQ-5D-5L), converted to utility scores. The median baseline utility (with quartiles) was 0.82 (0.68, 1.00). The median utility score improved slightly to 0.85 (0.75, 1.00) at 6 weeks, but this was not statistically significant, and remained relatively stable over the remaining course of follow up (see Table 14) (see [Table 14](#)). There was a significant increase in visual analogue scores (VAS) observed at 6 weeks (see *Supplementary Material - Table 8*).

Table 14: EQ-5D utility baseline and follow up scores.

Time point	Utility score (Q1, Q3 quartiles) Number of participants (n)
Baseline (reference)	0.82 (0.68,1.00) 272
6 weeks	0.85 (0.75,1.00) 156
6 months	0.85 (0.74,1.00) 175
1 year	0.84 (0.74,1.00) 124
2 years	0.84 (0.66, 1.00) 40

One relevant study on QoL changes associated with LAAO was identified in the literature. This was the study by Alli *et al.* (2013) [23]. This was a piggyback study performed on the participants of the PROTECT-AF study (in both WATCHMAN arms) using the Short-Form 12 Health Survey (SF-12) measured at baseline and 12 months. The authors reported statistically significant improvements ($p < 0.050$) in QoL in the domains of total physical score, physical functioning, and physical role limitation. This was predominantly due to declining utility scores in those receiving warfarin rather than improvements in those receiving LAAO. There was no statistical improvement in QoL in the mental component domain. The authors of the study hypothesised that improvements in physical wellbeing were due to the knowledge that LAAO was protecting them against stroke which empowered them to be more active. Conversely, subjects receiving warfarin continued to have INR monitoring, dietary restrictions, and were at risk of bleeding which may have curtailed their physical activity. The authors noted that the relatively small sample size and short follow up, as well as the potential for selection bias, were limitations of the study. This study, which compared patients on warfarin with those who had stopped taking warfarin (but were not contraindicated to it), lacks generalisability to the cohort represented by the CtE registry. Additionally, it did not use the EQ-5D system of QoL analysis favoured by UK guideline groups such as NICE.

Conclusion

CtE registry data showed no statistically significant differences in utility scores associated with the LAAO procedure, although there was a significant increase in VAS scores at 6 weeks. An increase of QoL in the domain of anxiety/depression domain would appear plausible (assuming reassurance conferred by lowering the risk of stroke) but has not been demonstrated by CtE. One published study of limited generalisability reported that compared with patients continuing with warfarin treatment, LAAO may improve QoL in the physical domains. More research would be required to verify this in the population represented by the CtE registry.

3.3.4 Question Four

“Are there any longer-term cardiac complications associated with the use of these devices (e.g. erosion with penetration through the wall of the atrium)?”

This question cannot be answered through analysis of CtE registry data, which is limited to 2 years maximum follow up within CtE funding. Out of 121 patients eligible for follow up at 2 years, 85 (70.2%) provided follow up data, with no long-term cardiac complications recorded.

The literature search performed by the EAC identified observational studies with 4 years follow up [34] and 5 years follow up [35], but potential longer term complications, such as atrial wall erosion, were not reported. It is likely that reporting of rare long-term complications will be restricted to case reports, but these were excluded from the EAC's literature identification process.

Conclusion

The registry was designed to identify potential longer-term complications over 5 years, but curtailed to 2 years due to funding restrictions. The EAC is unaware of any signal from the literature to indicate LAAO devices are associated with specific cardiac complications.

3.3.5 Question Five

“How many patients with atrial fibrillation with a contra-indication to oral anticoagulants (including previous significant bleed), or who have had a thromboembolic event despite being on oral anticoagulants, are candidates for left atrial appendage occlusion?”

This question cannot be fully addressed by data reported in the CtE registry, as the registry was principally concerned with recording explanatory variables and outcomes only in patients already selected for LAAO following a multi-disciplinary team (MDT) meeting. Of the 557 patients indicated for LAAO and eligible for CtE, 29 patients are recorded as not being treated and 24 have no record of successful device implantation (including one death). The reasons for this include unsuitable LAAO anatomy and presence of LAA thrombus. This indicates that, once, selected, the large majority of patients are suitable for the LAAO procedure. However, it is possible that patients undergoing MDT and not being selected for treatment were under reported.

The reasons for selection for LAAO treatment were recorded in the registry, with a 100% completion rate for patients funded through CtE (n=481). The reasons for treatment, together with the similar UK registry by Betts *et al.* (2016) [17], are reported in [Table 15](#).

Table 15: Reasons for LAAO treatment in the CtE registry and registry by Betts *et al.* (2016)

Reason	Proportion of patients (%)	
	CtE registry	UK registry (Betts)
Previous bleeding without anticoagulant therapy	23.4	12.1
Previous bleeding with anticoagulant therapy	57.8	52.8
Embolic event in spite of oral anticoagulant	3.3	3.5
Intolerant of oral anticoagulant	6.9	5.1
Poor control of oral anticoagulation	0.4	3.2
Primary or secondary prophylaxis regardless of issues with anticoagulation	0.2	N/R
Patient preference	0.4	5.4
At risk of severe bleeding	7.1	17.6
Other	0.6	N/R

Abbreviations. N/R - Not recorded.

The reasons for intervention with LAAO were similar for both registries, with a history of previous bleeding on oral anticoagulation being the indication for over 50% of cases. Less common indications included intolerance or poor control of oral anticoagulation, lifestyle issues, and the patient being considered to be at risk of serious bleeding without a prior history of it.

The absolute number of patients who could potentially benefit from LAAO in England (or any circumscribed area) is unknown but partly depends on strictness of the indication criteria. A survey of 86,671 AF patients found that only 2% of patients have an absolute contraindication to warfarin use, with 60% of these having had a prior intra-cranial haemorrhage [36]. However, in practice 13% of people with AF have been recorded as having a major contraindication to warfarin [37]. Novel oral anticoagulation drugs have a similar, but not exactly equivalent, range of contraindications, and may be suitable for some patients unable to take warfarin, for instance those with poor warfarin control (e.g. labile INRs). The prevalence of AF in England has been recently estimated to be 2.4%, which equates to 1.36 million people [38], with an estimated incidence of 1% in the over 65 population [39]. Given that the majority of the AF population contraindicated to anticoagulation are at relatively high risk of a thromboembolic event (e.g. 72% with CHA₂DS₂-VASc ≥ 2 [30]), this suggests the demand for LAAO nationally (England, with a population of 55 million [40]) may be between 19,500 people to 127,700 people, depending on the proportion of true contraindications for systemic pharmacotherapy. The incidence rate of new onset AF suggests that between 1400 and 9400 people aged over 65 years (comprising 1.7% of population [41]) may become eligible for LAAO each year. However, following consultation, clinical experts consider the higher estimates of demand are improbable.

Conclusion

Data from the CtE registry cannot be used to specifically answer this question. However, the registry does provide information on the reasons for selection for LAAO, which were primarily concerned with the patients being contraindicated to warfarin (or NOAC) treatment due to previous bleeding episodes. Depending on how contraindication to warfarin (or NOACs) is defined, the EAC has calculated, using a top down approach, that between 19,500 and 127,700 people might benefit from LAAO in England, with 1400 to 9400 people over 65 years becoming eligible for treatment each year, with the lower limits being more plausible.

3.3.6 Question Six

“Which devices are used to undertake LAAO and what are the device-specific efficacy and safety outcomes in CtE funded patients undergoing the procedure?”

The names and proportions of devices used in patients receiving LAAO reported in the CtE registry are listed in [Table 16](#).

Table 16: Names of devices and proportions used in patients reported in the CtE registry.

Device type	Number of procedures		Proportion of procedures (%)	
None	30		6.6	
WATCHMAN (Boston Scientific)	172		38.1	
AMPLATZER Cardiac Plug (ACP, St. Jude Medical)*	35	247	7.7	54.6
AMPLATZER Amulet*	212		46.9	
Coherex WaveCrest	3		0.7	

*Amulet is next generation of ACP device.

In general, there were insufficient follow up data to allow for disaggregated analysis and comparison of individual devices. It was not possible to determine if any device was associated with superior technical or procedural success as opened devices which were discarded before implantation were not recorded. For completeness, the EAC performed analysis comparing the two main device types (WATCHMAN vs. ACP/Amulet) in relation to efficacy in terms of death and neurological events, reported in [Appendix 7](#). There was no statistical difference seen between devices. Additionally, there were no significant differences reported associated with device type and major or minor complications (*Supplementary Material, Table 5 and 6*).

There are only limited data comparing efficacy and safety of devices in the literature. The UK registry by Betts *et al.* (2016) [17] compared outcomes with patients undergoing LAAO with the WATCHMAN with ACP/Amulet. The authors found that the WATCHMAN device was associated with the use of significantly more peri-procedural anticoagulation (48.8%) compared with ACP/Amulet (0.1%, $p = 0.0001$). There were no differences in terms of clinical outcomes.

The systematic review and meta-analysis by Wei *et al.* (2016) [21] compared pooled literature on the WATCHMAN, ACP, and PLAATO (discontinued) devices. The PLAATO device was associated with a significantly increased risk of all-cause death and cardiac or neurological death. The ACP device was associated with a significantly increased risk of thrombus formation on the device. Otherwise there were no significant differences detected between the WATCHMAN and ACP devices. A non-systematic review by Perotta *et al.* (2016) [42] reported on complications associated with LAAO devices. No significant differences between devices were reported.

Overall, the CtE registry and published data do not signal that there are differences in efficacy and safety between devices. A survey of European providers of LAAO found that around two thirds of centres exclusively use one type of device (principally WATCHMAN or ACP), with the remaining third using a mixture of devices [43]. In centres where a choice of devices is available, procedural safety and efficacy is likely to be confounded by patient selection.

Conclusion

There are insufficient data from the CtE registry to determine if the type of device used impacts on efficacy or safety. No evidence was identified in the EAC literature review that either WATCHMAN or ACP/Amulet is associated with superior clinical outcomes. Potential differences could be biased by patient selection, particularly in centres where a choice of devices is available (for instance allowing for anatomical matching).

3.3.7 Question Seven

“Is the frequency of complications seen with the intervention clinically acceptable?”

The following recommendation (1.1) was made regarding LAAO in NICE IPG349 [44]:

“Current evidence suggests that percutaneous occlusion of the left atrial appendage (LAA) is efficacious in reducing the risk of thromboembolic complications associated with non-valvular atrial fibrillation (AF). With regard to safety, there is a risk of life-threatening complications from the procedure, but the incidence of these is low. Therefore, this procedure may be used provided that normal arrangements are in place for clinical governance, consent and audit.”

The CtE registry has not detected a safety signal that contradicts this recommendation (see [Question One](#)). The EAC has not identified additional clinical evidence published since IPG349 (June 2010) that flags a concern for the efficacy or safety of LAAO.

Conclusion

The frequency of complications seen with LAAO in the registry is consistent with previous studies. Data on complication rates from the CtE registry will help direct informed patient consent for future procedures.

3.3.8 Question Eight

“Are clinical outcomes from left atrial appendage occlusion associated with particular patient characteristics (clinical or demographic)?”

Exploratory multivariate analysis was conducted using generalised linear modelling with binomial error distribution in order to estimate the effect of covariates. All numeric covariates were centred on their median before inclusion in multivariate analysis. However, it was found that the binary logistic regression analyses did not converge, or were over-fitted for the following measures:

- Device implanted outcome – covariates: procedure number (tertiles), gender, age, BMI, eGFR, LV ejection fraction, presence of LA thrombus, LA spontaneous echo contrast, LAAO morphology;

- In-hospital major and minor complications outcomes – covariates: procedure number (tertiles), gender, age, BMI, diabetes, eGFR, hypertension, medications, LV ejection fraction, presence of LA thrombus, LA spontaneous echo contrast, LAAO morphology and device used.

Therefore, a simpler set of covariates were tested for the CtE data and no significant association between age or sex and death was found (so being slightly older, younger, female, female and older, female and younger makes no difference to outcome in the CtE registry).

The PROTECT-AF trial [13] reported subgroup analysis on its primary endpoint (composite of stroke, cardiovascular or unexplained death, or systemic embolism at 18 months). It reported that there were no significant differences between the following subgroups: sex (male, female); age (<75 years, ≥ 75 Years); CHADS₂ score (1, ≥ 1); AF pattern (paroxysmal, persistent, and permanent); LAA ostium size (< median, ≥ median); LAA length (< median, ≥ median); left ventricular ejection fraction ([LVEF] < 60%, ≥ 60%).

The EWOLUTION registry [45], which focussed on procedural outcomes, did not find any relationship between subgroup type and procedural success. Additionally, risk of stroke, as measured by CHADS₂ and CHA₂DS₂-VASc scores, was not associated with increased risk of serious peri-procedural adverse events. However, an increased HAS-BLED score was associated with a significantly increased risk for adverse events, as was eligibility for anticoagulation. An observational study that included use of the WATCHMAN device (n = 219) found that the presence of a device leak (measured using TOE) was not associated with an increased risk of thromboembolism [46].

Conclusion

No significant associations were found between age or gender and death in the CtE registry. There is limited evidence in the literature that increased bleeding risk may be associated with worse peri-procedural outcomes. However, the presence of residual leak after closure does not appear to be directly associated with worse longer-term clinical outcomes.

3.3.9 Question Nine

“What are the full procedural costs of left atrial appendage occlusion to the NHS?”

Table 7 demonstrates that the forecast cost for an LAAO procedure ranges from about £9,500 to almost £13,330, with a central estimate of around £11,600. The device cost included in each scenario is £■■■■ per patient (£■■■■ for one device) and it accounts for about ■% to ■% of the total cost, depending on the scenario. This was calculated by using the number of devices opened per patient from the database. This also reported the devices used by manufacturer across centres. NHS Supply Chain provided the unit cost including VAT for each device for the main manufacturers. An additional 15% overhead was added to the NHS Supply Chain cost. These data enabled the EAC to calculate an average cost per device and per patient.

Under the central cost scenario the pre-operative pathway accounted for 7%, the procedure 77% and subsequent management 16% of total costs respectively.

3.3.10 Question Ten

“What are the potential cost savings for the NHS through provision of left atrial appendage occlusion for appropriate patients?”

‘Appropriate patients’ has been construed as patients with non-valvular atrial fibrillation and an absolute or relative contraindication to anticoagulation therapy.

Cost consequences analyses were undertaken to compare the costs and clinical outcomes of LAAO plus medical therapy with medical therapy alone. This is reported in a separate output from the EAC [52]. Where possible, data from the CtE registry were used to inform the parameters in the economic model. The key costs modelled over a 15-year time horizon for each comparator were:

- LAAO procedure costs;
- NHS and social care costs to manage haemorrhagic and ischaemic strokes and TIAs
- Costs of medication;
- Cost of bleeds for the events coded as such in the registry.

Total costs over the 15 years were reported from an NHS-only perspective and the wider NHS and social care perspective.

All patients entered the model aged 75 years, consistent with patients in the registry. In the LAAO arm, patients had a risk of strokes and bleeds at the rates observed at up to two years in the CtE registry (see event rates for ischaemic and haemorrhage strokes in Appendix 5). These rates were extrapolated to 15 years. Patients in the comparator arm received medical therapy and were estimated to have stroke and bleeding risks in accordance with their baseline CHA₂DS₂-VASc and HAS-BLED risk scores. The estimated cost of the LAAO procedure was calculated using resource use data from the registry and a costing template completed by participating sites. Medication use was taken from registry data (see response to Question Nine). The medicines regimen prescribed to patients before the procedure was assumed to apply to those in the medical therapy arm, whilst the medicines prescribed at two years post procedure were assumed to apply to patients after the LAAO procedure. NHS and social care costs associated with managing people with strokes were taken from a cost study conducted by the Sentinel Stroke National Audit Programme [53]. The study was based on patient-level health and social care costs for virtually all patients admitted to hospital with stroke in England and hence reflect current funding rules across the two sectors. Other costs were from national databases.

The model was run for a cohort of 1,000 people, with costs and patient outcomes aggregated for all patients for the 15-year time horizon (from 75 years to age 90 years). Costs were discounted at 3.5% per year.

The results from the base case are those which use the best point estimates for all the parameters that inform the model. Hence its results are the best estimate of the total costs.

Table 17 presents total costs for NHS components under the base case assumptions. The total NHS discounted cost of the LAAO pathway was estimated at £14,963 per patient. The procedure and bleeds recorded in the registry prior to discharge, accounted for 74% of these costs. Management of strokes and TIAs was the second largest component (15%), followed by medicines (9%), with subsequent bleeds accounting for the balance of 2%.

The total discounted cost of the medical therapy pathway was estimated at £8,392 per patient. Management of haemorrhagic and ischaemic strokes and TIAs was the largest component (76%), followed by medicines (18%), with bleeds accounting for the balance of 6%.

Hence the discounted NHS costs were £6,571 per person higher in the LAAO arm, a 78% increase on the cost of medical therapy only. The benefit from avoided stroke management and medication costs of almost £5,050 per patient with LAAO was insufficient to offset the initial procedure costs of about £11,620 per patient. The cost of the procedure would need to reduce by 57% to £5,050 before the NHS could achieve financial breakeven on the procedure.

If costs were not discounted then the additional cost per patient with LAAO was about £5,530, with a procedure cost reduction of 48% to £6,090 required before financial breakeven could be achieved.

Table 17: Total NHS costs per patient over a 15-year time horizon.

	Discounted costs per patient			Undiscounted costs per patient		
	LAAO	MT	Difference	LAAO	MT	Difference
Procedure & bleeds	£11,621	£0	£11,621	£11,621	£0	£11,621
Medication	£1,131	£1,561	−£429	£1,388	£1,895	−£507
Ischaemic stroke (NHS)	£1,419	£4,514	−£3,096	£1,767	£5,505	−£3,738
Haemorrhagic stroke (NHS)	£516	£1,669	−£1,153	£647	£2,051	−£1,404
TIA	£45	£160	−£115	£55	£193	−£138
Bleeds	£231	£488	−£257	£282	£585	−£303
Total	£14,963	£8,392	£6,571	£15,760	£10,230	£5,530

With the inclusion of social care costs both arms had similar costs, with the LAAO arm having total discounted costs of about £17,840 per patient and medical therapy £17,910 per patient, giving savings of about £70 per patient with LAAO. Evidence from the Stroke Audit costs [53] show that 60% of the costs to manage strokes are incurred in social care. Adopting an NHS perspective removed the majority of the stroke-related savings and switched the procedure from being cost-neutral, with the potential for a small cost saving to cost-incurring. More details on the costs with this wider perspective are available [52].

Sensitivity analyses identified that the model’s results were sensitive to changes in the relative risk reduction ratios for stroke following an LAAO procedure, the costs to manage strokes and the cost of the LAAO procedure. Removing the 15% overhead on the device cost included within the procedure cost in the base case, reduced the incremental increase in the total cost of the LAAO procedure to £5,680 per patient, from £6,571. Changes in other parameters had little impact on the absolute saving from LAAO over medical therapy.

3.3.11 Question Eleven

“Is left atrial appendage occlusion cost-effective from the perspective of the NHS?”

The response to Question Ten has identified that an economic model estimated an incremental cost to the NHS of about £6,570 per patient with an LAAO procedure compared with medical therapy only. When the wider health and social care perspective is adopted the model predicted that LAAO will not increase costs for the NHS and social care providers and potentially offers small savings of about £70 per patient.

The model also reported changes in clinical outcomes as identified in [Table 18](#).

Table 18: Comparison of clinical events per 1,000 patients over a 15-year horizon.

	LAAO	MT	Difference	Percentage change with LAAO
Ischaemic stroke	104	318	-214	-67%
Haemorrhagic stroke	32	97	-66	-68%
Subsequent strokes	28	91	-63	-69%
TIA	56	195	-139	-71%
Deaths	668	768	-100	-13%
Life years	11.1	9.9	1.2	12%

The model predicted that over 15 years the total number of strokes per 1,000 patients (ischaemic, haemorrhagic and subsequent strokes) may reduce from over 500 when patients are managed only on medical therapy to 164 following an LAAO procedure, a reduction in strokes of 343 or 68%. This is equivalent to a reduction in all-stroke risk from over 50% to 16%. Associated with this reduction were 100 forecast fewer deaths in the cohort receiving the LAAO procedure.

The reduction of 68% in the absolute risk of strokes is derived using the observed ischaemic and haemorrhagic stroke rates reported in the CtE registry at 2 years follow-up (see Appendix 5). The rate is consistent with the range of 66% to 87% reported in a number of clinical studies of LAAO compared with medical therapy (see Section 2 of the separate report [52]).

The key uncertainties with the clinical analyses are the validity of:

- Using the predicted stroke rates from the CHA₂DS₂-VASc tool for the medical therapy arm;

- Extrapolating the observed risk reduction in strokes from the registry at 2 years to 15 years;
- Extrapolating stroke costs over 15 years given the population are already aged 75 years.

In addition to the estimated life years gain of 1.2 years with LAAO compared with medical therapy over the 15 years, patients will receive a benefit from improved quality of life as a consequence of fewer strokes. This benefit was not measured in the CtE register although it did provide a measure of the procedure-related gain in quality of life (see response to Question 3).

The quality of life benefit associated with fewer strokes would be essential to inform a cost utility analysis where results are expressed as an incremental cost per quality adjusted life year. However, NICE advised the EAC that this form of analysis was not requested by NHS England.

With cost consequences analysis, the decision makers do not have a threshold-based decision rule to inform their decisions on cost effectiveness. Hence it is not possible for the EAC to advise from an NHS perspective, whether the additional cost to the NHS of £6,571 is cost-effective, given the forecast savings in strokes and deaths.

Adopting the wider NHS and social care perspective, the EAC can conclude the LAAO procedure is cost-effective compared to medical therapy. Costs are broadly equivalent between the two arms and LAAO is associated with material clinical and patient benefits from avoided strokes and associated reduced mortality.

3.3.12 Summary of Answers to NHS England Questions

Answers to the NHS England questions are summarised in [Table 19](#).

Table 19: Summary of NHS England answers

Final version of question, as amended by NICE following discussion with EAC	Summary answer (from registry data supplemented by published literature)
Can UK clinical teams reproduce the short and medium success rates for left atrial appendage occlusion reported in existing clinical trials, with equivalent or lower complication rates?	<p>Procedural efficacy data reported from the registry are largely complete and consistent with published data from RCTs and observational studies. Approximately nine in ten LAAO procedures result in procedural success (closure of LAA without major complication).</p> <p>Medium term efficacy (measured as the rate of neurological events, ischemic events and/or death) was higher in the registry compared with published data (mainly from RCTs). However, interpretation is limited by issues with generalisability because the patients in the registry were at greater risk of neurological events compared with the patients enrolled in RCTs (see Table 9).</p> <p>The rate of major complications reported by the CtE registry appears to be consistent with that published in the literature.</p>
Does left atrial appendage occlusion offer patients a lower risk of stroke or other embolic clinical events in the short and medium term compared with those that would have been predicted on the basis of validated risk scores?	Although limited by incomplete follow up, point estimate data reported by the CtE registry on the incidence of post-procedural ischaemic events is consistent with LAAO conferring a protective effect.
Is left atrial appendage occlusion associated with an improved quality of life?	CtE registry data showed no significant changes in individual quality of life (EQ-5D) components or utility scores over time. The median visual analogue scale (VAS) score at 6 weeks showed a statistically significant improvement compared to pre-procedure. One QoL study identified in the literature reported LAAO was associated with significant improvements in QoL in the physical domains after 1 year.
Are there any longer-term cardiac complications associated with the use of these devices (e.g. erosion with penetration through the wall of the atrium)?	The registry did not follow up patients for sufficiently long enough to answer this question.

Final version of question, as amended by NICE following discussion with EAC	Summary answer (from registry data supplemented by published literature)
How many patients with atrial fibrillation with a contra-indication to oral anticoagulants (including previous significant bleed), or who have had a thromboembolic event despite being on oral anticoagulants, are candidates for left atrial appendage occlusion?	This question could not be answered using data from the registry. Using published data, the EAC has estimated that the unmet need of LAAO could range from 19,500 to 127,700 people, with 1400 to 9400 patients over 65 years becoming eligible each year. This represents a crude estimate and is dependent on the precise indication definitions for LAAO.
Which devices are used to undertake LAAO and what are the device-specific efficacies and safety outcomes in CtE funded patients undergoing the procedure?	The CtE registry reported that the ACP/Amulet devices and WATCHMAN devices dominated the market with 54.6% and 38.1% usage respectively. An analysis of efficacy in terms of death and neurological event between WATCHMAN and ACP/Amulet devices showed no statistical differences between the two manufacturers. There was no significant difference reported in the proportion of major and minor complications.
Is the frequency of complications seen with the intervention clinically acceptable? (This question has already been considered by the NICE Interventional Procedures Advisory Committee when developing the IP guidance on this procedure. If the CtE project indicated that this procedure has a more risky safety profile than appears in the current NICE Interventional Procedures guidance, it could potentially lead to NICE updating the guidance, in line with normal processes).	There was no safety flag identified from the registry that would require an update of NICE IPG349.
Are clinical outcomes from left atrial appendage occlusion associated with particular patient characteristics (clinical or demographic)?	There were insufficient data reported in the registry to allow for subgroup analysis.
What are the full procedural costs of left atrial appendage occlusion to the NHS?	The central estimate of the cost of an LAAO procedure is about £11,600, range £9,500 to £13,300.
What are the potential cost savings for the NHS through provision of left atrial appendage occlusion for appropriate patients?	The LAAO procedure plus medical therapy is estimated to have higher NHS-related costs of about £6,570 per patient compared to medical therapy only over a 15-year time horizon from the date of the procedure.

Final version of question, as amended by NICE following discussion with EAC	Summary answer (from registry data supplemented by published literature)
Is left atrial appendage occlusion cost-effective from the perspective of the NHS?	<p>In a cohort of 1,000 patients with similar characteristics to those in the registry, over a 15-year period, the LAAO procedure plus medical therapy was estimated to reduce strokes from over 500 when patients are managed only on medical therapy to 164, a reduction in strokes of 343 or 68%. Associated with this reduction were 100 forecast fewer deaths in the cohort receiving the LAAO procedure, giving a life-year gain of 1.2 years. The EAC cannot advise whether the additional cost to the NHS of £6,570 per patient is cost-effective given the forecast savings in strokes and deaths.</p>

Section 4: Discussion

4.1 SUMMARY OF FINDINGS FROM PRIMARY DATA COLLECTION (CTE DATABASE)

The CtE registry enrolled a total of 571 patients, of which 525 were included (with 46 patients not meeting inclusion criteria). Included patients had a median age of 75 years, median CHA₂DS₂-VASc of 4, and median HAS-BLED score of 4. Five hundred and nine patients (97.0%) recorded both admission and discharge data, allowing for procedural analysis. Medium term safety and efficacy outcomes were reported in follow-up information in 82.4% procedures at 6 weeks, 80.9% at 6 months, 76.1% at 1 year and 70.2% at 2 years. There were no significant difference in clinical characteristics between patients who were followed up and all patients at baseline except for device used.

Most patients received either a WATCHMAN (38.1%) or Amplatzer (Amulet/ACP) device (54.6%). Device implantation was technically successful in 93.6% of patients, and was regarded as a procedural success in 89.0% of cases (technical success in absence of major complication). The large majority of patients had one night stay in hospital. There was an in-hospital rate of major complications (defined as death, neurological event, pericardial effusion requiring intervention, embolization, surgical intervention, major vascular injury, major bleed, myocardial infarction, acute kidney injury at Stage 2 or 3 and endocarditis) of 5.5% and minor complication rate of 4.6%.

The primary efficacy outcome of the CtE registry, a composite measure of all-cause mortality and neurological events, was 9.8 (95% CI 7.0 to 13.4) events per 100 PY, over an aggregated follow up period of almost 400 person-years. Of the 19 neurological events reported, 10 were ischaemic and 4 were haemorrhagic in origin, with 4 of undetermined cause and 1 CVA/RIND reported. The crude event rate for ischaemic events was 2.6 (95% CI 1.3 to 4.8) events per 100 PY follow up. Two deaths were attributed to ischaemic stroke.

The central estimate of the cost of the procedure was £11,600 (range £9,500 to £13,300). About ■■■ the cost was associated with the device (■■%), with additional costs being incurred by investigations (■■%); staffing costs (■■%); consumables (5%); hospital stay (5%); theatre time (4%), and outpatient follow-up (2%).

Analysis of limited EQ-5D data indicated that the use of LAAO had minimal impact on quality of life in any of the domains, as would be expected with a preventative intervention.

4.2 RESULTS IN THE CONTEXT OF OTHER STUDIES

The EAC performed a literature search which identified key studies published on percutaneous LAAO through the endocardial approach. Two RCTs and three observational studies were selected from the body of evidence as being most useful in providing data to contextualise the results of the CtE registry.

The CtE registry provided good data on the procedural efficacy and in hospital safety of LAAO. These data were consistent with those reported in the literature, indicating that English centres participating in CtE were performing the procedure to an expected standard.

Medium-term efficacy data (neurological events and death) was available in 70% of patients at 2 years follow up. There was some indication that the efficacy of LAAO in preventing these events was inferior to that seen for similar outcomes in the RCTs and observational registries, with the lower CI not overlapping with CIs or point estimates reported in the published literature (see Table 10). The neurological event rate also appeared to be substantially higher in the CtE registry compared with published studies. Two deaths were recorded in the registry as being due to ischaemic stroke. However, no conclusions could be drawn on the relative efficacy and safety of LAAO because patients enrolled in the registry were known to be at higher risk of ischaemic events than those reported in the RCTs.

Currently the only direct, comparative data published on LAAO is restricted to the PROTECT-AF [13] and PREVAIL [14] RCTs. These non-inferiority trials, discussed in the EAC literature review [7], did not provide evidence of equivalence of the WATCHMAN device with oral anticoagulation. Furthermore, they did not investigate the efficacy and safety of LAAO in the population of interest, which are primarily people who are unable to take warfarin or NOACs. This gap in the evidence base has not been fully addressed by observational studies, which lack a control arm.

Recently, the protocol for a new RCT has been published which should provide clarity on the effectiveness of LAAO in patients unable to receive oral anticoagulation. The Assessment of the WATCHMAN Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) trial [47] will be a relatively large trial ($n = 888$) with long-term outcomes (5 years) performed in patients ($\text{CHA}_2\text{DS}_2\text{-VASc} \geq 2$) contraindicated to warfarin. The RCT will compare the safety and efficacy of the WATCHMAN device with the use of antiplatelet monotherapy or no treatment. This RCT should provide valuable data that may resolve the uncertainties discussed. However, the trial is not due for completion until 2023.

The EAC identified 15 economic studies, of which 1 was considered to have good internal and external validity [48]. This study, which used data from a UK hospital registry, reported that LAAO was potentially cost-saving over a time horizon of 10 years compared against other therapies such as anticoagulation. Other studies have also indicated LAAO may be cost-effective in the longer-term, but these studies are limited in generalisability due to the perspective, setting and application of clinical data (which were derived from the non-generalisable PROTECT-AF and PREVAIL trials of the WATCHMAN device).

In summary, the EAC has identified some concerns regarding the efficacy of LAAO reported in the registry compared with the published literature. Although procedural efficacy and in-hospital complications appear to be broadly consistent, medium-term efficacy rates appear to be inferior in the registry compared with the published literature. The EAC considered that this was likely to be due to the limited generalisability of the published studies, particularly the RCTs which featured a different (lower risk) population and intervention (which included warfarin). However, if LAAO in the CtE setting is not as effective as predicted, this could also have consequences for the economic benefits of the procedure. Therefore, further research may be warranted.

4.3 LIMITATIONS, STRENGTHS, AND FUTURE PROPOSALS

4.3.1 Limitations

The CtE registry was a single armed study and thus comparisons had to be made implicitly with results published in the literature [48]. This had 2 limitations. Firstly, no statistical or quantitative comparisons could be made with the comparator of interest, which was conservative medical management (use of antiplatelet drugs). Secondly, much of the published literature was not directly generalisable to the data collected from the CtE registry, thus inferences of equivalence (or not) are subject to considerable uncertainty.

Other specific and non-specific limitations with the registry include the following:

- The registry was funded for a maximum follow up of 2 years. This meant that longer-term efficacy outcomes or data on longer-term complications were not available and questions pertaining to these were not answerable (see [Question Four](#));
- In addition to the 2-year cut off point, most patients were not eligible for assessment at this time point because of the timeframe of the study and associated deadlines. Of the 525 patients eligible for analysis ([Appendix 1](#)), only 121 (25.8%) had an LAAO device implanted, were still alive at the previous follow-up hospital visit and had reached 2 years since their date of procedure (*Supplementary Material – Table 3*). It is possible that this cohort of patients receiving treatment early in the project may not be representative of the overall cohort (e.g. because patients were prioritised on the waiting list due to pressing clinical needs, or because of the potential for learning curve issues);
- Kaplan-Meier analysis assumed “no event” status of patients unless an event was recorded. Thus the analysis relies on complete reporting of all event data. Patients who are lost to follow up are censored from the analysis, but it is unclear if these are representative of the overall cohort. Finally, patients may have multiple events (excluding death), but the Kaplan-Meier protocol only analyses time to first event.

4.3.2 Strengths

The registry had several strengths. Firstly, the registry enrolled indicated patients consecutively and represented a pragmatic real-world cohort of patients receiving treatment with LAAO as performed in the NHS. Thus the external applicability of the registry to future practice is high, although improvements in the procedure protocol and the learning curve effect may ultimately lead to improved outcomes.

Secondly, following an initial disappointing response from centres in providing follow-up data, this improved considerably such that there was about 400 PY follow up available for analysis. This improved the precision and certainty of time-to-event analysis. Where follow up was achieved (for 70.2% of eligible patients [n = 121] at 2 years), the completion of individual data fields varied, but overall, data completeness was regarded as good. The number reporting results for each data field are presented in the Supplementary Material to this report.

Thirdly, the CtE registry reported important clinical outcomes. In addition, the registry captured quality of life data and, through the use of *pro formas* directed at a centre level, estimated the cost of the procedure. This information may be of use in future cost-effectiveness studies.

In addition to the strengths (and limitations) of the registry, it should be considered that it provided patients with access to treatment they might have otherwise forgone. This is important in the case of this population with AF, as LAAO represents the only treatment modality (other than generally ineffectual antiplatelet treatment) available to them in the prevention of ischaemic stroke.

4.3.3 Future Proposals

The registry analysis would be more robust with data linkage to the ONS (Office of National Statistics) mortality dataset, to validate calculated mortality rates in the CtE cohort and provide greater coverage. This could be potentially continued beyond the final follow up date of the study (2 years). Potentially, data linkage to HES (Hospital Episodes Statistics) could also provide further validation and coverage of neurological event data, as well as informing cost information. At the time of submission of this final CtE report to NHS England, NICOR are preparing a Data Access Request Service (DARS) application to NHS Digital for data linkage.

Section 5: Conclusion

The LAAO CtE registry included 525 patients who had AF and were at high risk of ischaemic stroke (median CHA₂DS₂-VASc of 4) and had a relative or absolute contraindication to oral anticoagulation (warfarin or NOAC). Patients were followed up to 2 years after the procedure was performed, and important clinical outcomes were determined. As the registry was single-armed, implicit comparisons with published literature, previously identified in a bespoke review [3], were made in order to answer 11 questions asked by NHS England.

The registry reported a technical success rate of 93.6% (91.1% to 95.6%) and a procedural success rate of 89.0% (86.0% to 91.6%), indicating the procedure was successful in about 9 out of 10 patients. There was an in-hospital major complication rate of 5.5% (3.7 to 7.8%). These short-term results were consistent with values reported in the literature.

Following discharge from hospital, there were 10 ischaemic events reported by the registry over the course of about 400 PY, giving a rate of 2.6 (95% CI 1.3 to 4.8) per 100 PY, which was a lower rate than that observed in epidemiological studies of patients receiving no treatment. Twenty five deaths were reported in total, five of which occurred in hospital. The registry reported a composite of (all cause) death or neurological event rate of 9.8 (7.0 to 13.4) per 100 PY; this event rate was substantially higher than those reported in RCTs in patients receiving LAAO [13, 14]. However, an important limitation of this comparison was that the registry and RCT populations, and to a lesser extent interventions, were not generalisable. That is, it has been shown that patients enrolled into the CtE registry had a greater underlying risk of stroke compared with those enrolled in the RCTs.

The registry did not report important improvements in quality of life associated with LAAO, and was not designed to detect long-term adverse events beyond the 2 year time horizon. Although it was not possible to directly estimate the amount of people who may benefit from the intervention in England, it is likely to number in the thousands. An additional survey performed by the EAC indicated the overall cost per procedure was on average £11,600, with a range of £9,500 to £13,300.

It is known that the risk of thromboembolic stroke in people with AF can be significantly reduced using oral anticoagulation in the form of warfarin or NOACs. For people with genuine contraindications to these drugs, LAAO may be the only viable treatment option. The CtE registry has demonstrated that LAAO may reduce stroke risk compared to historical controls; however, it has not demonstrated equivalence of efficacy compared with patients participating in RCTs who were not contraindicated to warfarin. At present, there are no comparative studies that demonstrate the efficacy of LAAO in the population represented by the CtE. This issue should be resolved with the publication of the ASAP-TOO trial [47], but this is some years away. In the meantime, the evidence for the use of LAAO in patients contraindicated to oral anticoagulation, including evidence generated from this registry, is restricted to uncontrolled observational studies, and as such is somewhat equivocal.

Economic modelling suggests that the procedure will increase costs to the NHS by about £6,570 but be financial neutral if a wider NHS and social care perspective is adopted. Based on the registry recorded stroke events rates at two years, extrapolated over 15 years, the procedure is forecast to deliver large reductions in the potential number of strokes and deaths compared with medical therapy. With cost consequences analysis, decision makers do not adopt a threshold-based decision rule to inform their decisions on cost effectiveness. Hence it is not possible for the EAC to advise from an NHS perspective, whether the additional cost to the NHS of £6,571 is cost-effective given the forecast savings in strokes and deaths. If the wider NHS and social care perspective is adopted the EAC can advise the procedure is cost-effective, having similar costs to current practice but material clinical benefits

Section 6: Acknowledgements

External Assessment Centre (EAC) Administrator in Newcastle, Emma Bellios, acted as secretary and produced minutes of meetings and teleconferences throughout the duration of the cardiac CTE project.

EAC literature searches were conducted by Mick Arber, Senior Information Specialist at York Health Economics Consortium.

Roseanne Jones, Research Scientist within the Newcastle EAC team, supported literature sifting as a second reviewer to Iain Willits and Helen Cole.

Julie Burn, Clinical Scientist in Clinical Computing at Newcastle, acted as an adviser to Kim Keltie and Sam Urwin, in support of their data analysis work for cardiac CTE.


Section 7: References

1. Willits I, Jones R, Bousfield D, Arber M, Cole H, Sims AJ. OUTPUT ONE: Recommendations on three NHS England Commissioning through Evaluation (CtE) registry draft datasets for MitraClip, LAAO and PFO Closure cardiovascular procedures. In: EAC NY, editor. Unpublished; 2014.
2. Cole H, Willits I, Craig J, Sims AJ. OUTPUT TWO: Data quality monitoring process. Unpublished; 2015.
3. Willits I, Craig J, Cole H, Urwin S, Sims AJ. OUTPUT THREE: Draft registry data analysis protocol - LAAO. In: EAC NY, editor. Unpublished; 2015.
4. NHS England. Left Atrial Appendage Occlusion CtE Provider Selection Confirmed (Specialised Services Circular). 2014.
5. National Institute for Health and Care Excellence. Overview (IP310): Interventional procedure overview of percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism. London; 2010.
6. R Core Team. . R Foundation for Statistical Computing V, Austria, . URL <http://www.R-project.org/>. R: A language and environment for statistical computing. Vienna; 2013.
7. Willits I, Jones R, Arber M, Cole H. RX085 Commissioning through Evaluation (CTE) registry of 3 cardiovascular procedures. LAAO literature review document. Unpublished; 2016.
8. Agency for Healthcare Research and Quality (AHRQ). Registries for evaluating patient outcome: a user's guide: Volume 1. 3rd ed. Rockville, MD; 2012.
9. Agency for Healthcare Research and Quality (AHRQ). Registries for evaluating patient outcome: a user's guide: Volume 2. 3rd ed. Rockville, MD; 2012.
10. Department of Health. NHS reference costs 2015 to 2016. 2016.
11. Curtis L, Burns A. Unit Costs of Health and Social Care 2016. 2016.
12. Moher D, Liberati A, Tetzlaff J, Altman G, Prisma PRISMA. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS medicine*. 2009;6(7).
13. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. *Lancet*. 2009 Aug 15;374(9689):534-42.
14. Holmes DR, Jr., Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.[Erratum appears in *J Am Coll Cardiol*. 2014 Sep 16;64(11):1186]. *Journal of the American College of Cardiology*. 2014 Jul 8;64(1):1-12.
15. Boersma LVA, Schmidt B, Betts TR, Sievert H, Tamburino C, Teiger E, et al. EWOLUTION: Design of a registry to evaluate real-world clinical outcomes in patients with AF and high stroke risk-treated with the WATCHMAN left atrial appendage closure technology. *Catheterization & Cardiovascular Interventions*. 2016 Sep;88(3):460-5.
16. Boersma LV, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B, et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. *Heart Rhythm*. 2017 Sep;14(9):1302-8.
17. Betts TR, Leo M, Panikker S, Kanagaratnam P, Koa-Wing M, Davies DW, et al. Percutaneous left atrial appendage occlusion using different technologies in the United Kingdom: A multicenter registry. *Catheterization & Cardiovascular Interventions*. 2016 Sep 21;21(1-9).
18. Tzikas A, Shakir S, Gafoor S, Omran H, Berti S, Santoro G, et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. *EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology*. 2016 Feb;11(10):1170-9.

19. Holmes DR, Jr., Doshi SK, Kar S, Price MJ, Sanchez JM, Sievert H, et al. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. *Journal of the American College of Cardiology*. 2015 Jun 23;65(24):2614-23.
20. Koifman E, Lipinski MJ, Escarcega RO, Didier R, Kiramijyan S, Torguson R, et al. Comparison of Watchman device with new oral anti-coagulants in patients with atrial fibrillation: A network meta-analysis. *International Journal of Cardiology*. 2016 Feb 15;205:17-22.
21. Wei Z, Zhang X, Wu H, Xie J, Dai Q, Wang L, et al. A meta-analysis for efficacy and safety evaluation of transcatheter left atrial appendage occlusion in patients with nonvalvular atrial fibrillation. *Medicine (Baltimore)*. 2016 Aug;95(31):e4382.
22. Xu H, Xie X, Wang B, Ma S, Wang F. Efficacy and Safety of Percutaneous Left Atrial Appendage Occlusion for Stroke Prevention in Nonvalvular Atrial Fibrillation: A Meta-analysis of Contemporary Studies. *Heart Lung Circ*. 2016 May 2;2:2.
23. Alli O, Doshi S, Kar S, Reddy V, Sievert H, Mullin C, et al. Quality of life assessment in the randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) trial of patients at risk for stroke with nonvalvular atrial fibrillation. *Journal of the American College of Cardiology*. 2013 Apr 30;61(17):1790-8.
24. Panikker S, Lord J, Jarman JWE, Armstrong S, Jones DG, Haldar S, et al. Outcomes and costs of left atrial appendage closure from randomized controlled trial and real-world experience relative to oral anticoagulation. *European Heart Journal*. 2016 Mar 1;1:3470-82.
25. Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. *Circulation*. 2011 Feb 1;123(4):417-24.
26. Reddy VY, Mobius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). *Journal of the American College of Cardiology*. 2013 Jun 25;61(25):2551-6.
27. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997 Sep 13;315(7109):629-34.
28. Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, Neuzil P, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation a randomized clinical trial. *JAMA - Journal of the American Medical Association*. 2014 19 Nov;312(19):1988-98.
29. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA*. 2001 Jun 13;285(22):2864-70.
30. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest*. 2010 Feb;137(2):263-72.
31. Chen JY, Zhang AD, Lu HY, Guo J, Wang FF, Li ZC. CHADS2 versus CHA2DS2-VASc score in assessing the stroke and thromboembolism risk stratification in patients with atrial fibrillation: a systematic review and meta-analysis. *J Geriatr Cardiol*. 2013 Sep;10(3):258-66.
32. National Clinical Guideline Centre. Atrial fibrillation: the management of atrial fibrillation. London; 2014.
33. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. *BMJ*. 2011 Jan 31;342:d124.
34. Santoro G, Meucci F, Stolcova M, Rezzaghi M, Mori F, Palmieri C, et al. Percutaneous left atrial appendage occlusion in patients with non-valvular atrial fibrillation: implantation and up to four years follow-up of the AMPLATZER Cardiac Plug. *EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology*. 2016 Feb;11(10):1188-94.

35. Wiebe J, Franke J, Lehn K, Hofmann I, Vaskelyte L, Bertog S, et al. Percutaneous Left Atrial Appendage Closure With the Watchman Device: Long-Term Results Up to 5 Years. *Jacc: Cardiovascular Interventions*. 2015 Dec 28;8(15):1915-21.
36. Steinberg BA, Greiner MA, Hammill BG, Curtis LH, Benjamin EJ, Heckbert SR, et al. Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation. *Cardiovasc Ther*. 2015 Aug;33(4):177-83.
37. Kalra L, Yu G, Perez I, Lakhani A, Donaldson N. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. *BMJ*. 2000 May 06;320(7244):1236-9.
38. Public Health England. Atrial fibrillation prevalence estimates in England: Application of recent population estimates of AF in Sweden. 2015.
39. Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. *Health Technol Assess*. 2005 Oct;9(40):iii-iv, ix-x, 1-74.
40. Office for National Statistics. Population Estimates for UK, England and Wales, Scotland and Northern Ireland: mid-2015. 2015 [cited 2017 19th May]; Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/bulletins/annualmidyearpopulationestimates/latest>
41. Office for National Statistics. Overview of the UK population: February 2016. 2016 [cited 2017 19th May]; Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/articles/overviewoftheukpopulation/february2016>
42. Perrotta L, Bordignon S, Dugo D, Furnkranz A, Konstantinou A, Ricciardi G, et al. Complications from left atrial appendage exclusion devices. *Journal of Atrial Fibrillation*. 2014 June-July;7(1):66-72.
43. Pison L, Potpara TS, Chen J, Larsen TB, Bongiorni MG, Blomstrom-Lundqvist C, et al. Left atrial appendage closure-indications, techniques, and outcomes: results of the European Heart Rhythm Association Survey. *Europace*. 2015 Apr;17(4):642-6.
44. National Institute for Health and Clinical Excellence. Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism (IPG349). London: National Institute for Health and Care Excellence (NICE); 2010.
45. Boersma LVA, Schmidt B, Betts TR, Sievert H, Tamburino C, Teiger E, et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. *European Heart Journal*. 2016 Aug;37(31):2465-74.
46. Pillarisetti J, Reddy YM, Gunda S, Swarup V, Lee R, Rasekh A, et al. Endocardial (Watchman) vs epicardial (Lariat) left atrial appendage exclusion devices: Understanding the differences in the location and type of leaks and their clinical implications. *Heart Rhythm*. 2015 Jul;12(7):1501-7.
47. Holmes DR, Reddy VY, Buchbinder M, Stein K, Elletson M, VBergmann MW, et al. The Assessment of the Watchman Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) trial. *American Heart Journal*. 2017;189(0):69.
48. AHRQ. Role of Single Group Studies in Agency for Healthcare Research and Quality Comparative Effectiveness Reviews. 2013.
49. National Clinical Guideline Centre. Preoperative tests Routine preoperative tests for elective surgery. Appendix M: Economic considerations for Delphi. 2016 [cited 2018 3rd January]; Available from: <https://www.nice.org.uk/guidance/ng45/evidence/appendix-m-economic-considerations-for-delphi-pdf-87258149464>
50. Information service Division. Theatre Services. October 2016. 2016 [cited 2018 3rd January]; Available from: <http://www.isdscotland.org/Health-Topics/Finance/Costs/Detailed-Tables/Theatres.asp>
51. BNF. British National Formulary Online. 2017 June 2017 [cited 2017 18th December]; Available from: <https://www.bnf.org/products/bnf-online/>

Appendix 1 – Data Flow Diagram



Appendix 2 – Patient Characteristics

Patient characteristics for all eligible LAAO patients and those with recorded information from follow-up appointments.

Patient characteristic†	All eligible LAAO patients (n=525)	All patients with follow-up (n=440)	p-value
Female	164 (31.3%)	139 (31.7%)	0.94
Age, years median (Q1,Q3) [range]	75 (70,80) [43-92]	75 (70,80) [43-92]	0.76
BMI, kg/m ² median (Q1,Q3) [range]	27.1 (24.3,31.1) [10.1-46.1]	27.6 (24.5,31.2) [10.0-46.1]	0.50
Ethnic origin:			0.85
Caucasian	501 (96.5%)	422 (97.0%)	
Black	6 (1.2%)	5 (1.1%)	
Asian	8 (1.5%)	4 (0.9%)	
Other	4 (0.8%)	4 (0.9%)	
Diabetes:			0.97
No	382 (73.6%)	325 (74.0%)	
Yes (not insulin)	120 (23.1%)	101 (23.0%)	
Yes (insulin)	17 (3.3%)	13 (3.0%)	
eGFR median (Q1,Q3) [range]	68 (54,82) [6-274]	69 (55,82) [6-262]	0.64
CHADS ₂ median (Q1,Q3) [range]	3 (2,4) [0-6]	3 (2,4) [0-6]	0.97
CHA ₂ DS ₂ -VASc median (Q1,Q3) [range]	4 (3,5) [0-9]	4 (3,5) [0-8]	0.97
HAS-BLED median (Q1,Q3) [range]	4 (3,5) [1-6]	4 (3,5) [1-6]	0.92
NYHA			0.99
No limitation of physical activity	186 (42.4%)	153 (41.9%)	
Slight limitation of ordinary physical activity	194 (44.2%)	164 (44.9%)	
Marked limitation of ordinary physical activity	54 (12.3%)	445 (12.1%)	
Symptoms at rest or minimal activity	5 (1.1%)	4 (1.1%)	
EHRA AF			1.00
No AF-related symptoms	218 (52.0%)	183 (52.0%)	
Mild symptoms; normal daily activity not affected	184 (43.9%)	155 (44.0%)	
Severe symptoms; normal daily activities affected	15 (3.6%)	13 (3.7%)	
Disabling symptoms; normal daily activity discontinued	2 (0.5%)	1 (0.3%)	
Smoking status:			0.86
Never smoked	255 (54.3%)	221 (55.1%)	
Ex-smoker	202 (43.0%)	167 (41.6%)	
Current smoker	13 (2.8%)	13 (3.2%)	

Patient characteristic†	All eligible LAO patients (n=525)	All patients with follow-up (n=440)	p-value
Dialysis status:			1.00
No	505 (99.0%)	430 (99.1%)	
Acute	1 (0.2%)	0 (0.0%)	
Chronic	4 (0.8%)	4 (0.9%)	
Rhythm history:			0.99
No arrhythmias	5 (1.0%)	4 (0.9%)	
Paroxysmal AF/flutter	143 (27.4%)	115 (26.3%)	
Persistent AF/flutter	83 (15.9%)	69 (15.8%)	
Permanent AF/flutter	288 (55.3%)	247 (56.5%)	
Atrial tachycardia	1 (0.2%)	1 (0.2%)	
Other symptomatic arrhythmia	1 (0.2%)	1 (0.2%)	
Pre-op heart rhythm:			0.97
Arrhythmia	417 (80.5%)	355 (81.1%)	
Sinus	94 (18.1%)	77 (17.6%)	
Paced	7 (1.4%)	6 (1.4%)	
Hypertension:			0.72
No	157 (30.3%)	128 (29.2%)	
Yes	355 (68.4%)	304 (69.2%)	
Yes, systolic BP > 160 mmHg	7 (1.3%)	7 (1.6%)	
CCF (heart failure)	56 (10.9%)	45 (10.3%)	0.83
MI	101 (19.5%)	84 (19.2%)	0.93
Peripheral vascular disease	34 (6.7%)	29 (6.8%)	1.00
Significant liver disease	8 (1.6%)	5 (1.2%)	0.78
Neurological disease:			0.98
Yes, CVA	258 (49.7%)	220 (50.1%)	
Yes, other	87 (16.8%)	74 (16.9%)	
No	174 (33.5%)	145 (33.0%)	
Significant valve disease	38 (7.5%)	33 (7.7%)	1.00
Asymptomatic carotid disease:			0.96
Carotid disease excluded	180 (48.4%)	151 (48.7%)	
Carotid disease (<50% stenosis)	19 (5.1%)	18 (5.8%)	
Carotid disease (≥50% stenosis)	6 (1.6%)	4 (1.3%)	
No carotid imaging done	167 (44.9%)	137 (44.2%)	
Previous significant bleed:			0.99
No	63 (12.4%)	51 (11.8%)	
Yes (life threatening/disabling)	211 (41.5%)	179 (41.5%)	
Yes (major)	200 (39.3%)	173 (40.1%)	
Yes (minor)	35 (6.9%)	28 (6.5%)	
Previous peripheral embolism	9 (1.8%)	7 (1.6%)	1.00
Medications (pre-op):			0.99
Single antiplatelet	137 (26.6%)	111 (25.8%)	
Dual antiplatelet	28 (5.4%)	26 (6.0%)	
Anticoagulant alone	75 (14.5%)	67 (15.5%)	
Antiplatelet(s) & Anticoagulant(s)	6 (1.2%)	6 (1.4%)	
Other	56 (10.9%)	46 (10.7%)	
None	214 (41.5%)	175 (40.6%)	
Concomitant NSAID use	30 (6.1%)	29 (6.9%)	0.69
Previous interventions:			
Coronary revascularisation	93 (18.1%)	77 (17.7%)	0.93

Patient characteristic†	All eligible LAAO patients (n=525)	All patients with follow-up (n=440)	p-value
MV surgery	12 (2.3%)	9 (2.1%)	0.82
AV procedure	20 (3.9%)	15 (3.5%)	0.86
LAA procedure	18 (3.6%)	11 (2.6%)	0.45
CRM device therapy	74 (14.5%)	63 (14.6%)	1.00
Ablation therapy	36 (7.0%)	30 (6.9%)	1.00
DC cardio-/atrio-version(s)	55 (11.7%)	47 (11.8%)	1.00
Atrial septal procedure	2 (0.4%)	1 (0.2%)	1.00
LV ejection fraction:			0.96
Good (>50%)	403 (80.4%)	164 (80.8%)	
Moderate (30-50%)	75 (15.0%)	30 (14.8%)	
Poor (<30%)	23 (4.6%)	9 (4.4%)	
LA thrombus	19 (3.8%)	1 (0.5%)	0.11
LA spont. echo contrast (SEC):			1.00
None	346 (69.2%)	297 (69.9%)	
Yes – only in LA appendage	71 (14.2%)	59 (13.9%)	
Yes – elsewhere in LA	26 (5.2%)	21 (4.9%)	
Yes – LAA and elsewhere	57 (11.4%)	48 (11.3%)	
Aortic atheroma in arch:			0.98
Not imaged	391 (77.4%)	330 (76.7%)	
Grade 1	101 (20.0%)	87 (20.2%)	
Grade 2	11 (2.2%)	11 (2.6%)	
Grade 3	1 (0.2%)	1 (0.2%)	
Grade 4	1 (0.2%)	1 (0.2%)	
LAAO morphology:			1.00
Single straight windsock	193 (40.0%)	165 (39.9%)	
Single chicken wing	87 (18.0%)	75 (18.1%)	
Bilobe	128 (26.5%)	112 (27.1%)	
Trilobe	10 (2.1%)	8 (1.9%)	
Retroverted	19 (3.9%)	17 (4.1%)	
Broccoli	41 (8.5%)	33 (8.0%)	
Other	5 (1.0%)	4 (1.0%)	

Note:
† Not all data fields were complete for every patient at baseline and follow up. The percentages presented in this table are calculated using the number of patients with each characteristic reported as the denominator.

Appendix 3 – Procedural Characteristics

Procedural characteristics for all eligible LAAO patients and those with recorded information from follow-up appointments.

Procedural characteristic [†]	All eligible LAAO patients (n=525)	All patients with follow-up (n=440)	p-value
Treating Hospital			1.00
Liverpool Heart & Chest Hospital NHS Foundation Trust	86 (16.4%)	81 (18.4%)	
University Hospital of North Staffordshire NHS Trust	63 (12.0%)	54 (12.3%)	
Oxford University Hospitals NHS Trust	66 (12.6%)	61 (13.9%)	
Brighton & Sussex University Hospitals NHS Trust	58 (11.0%)	44 (10.0%)	
University Hospitals Leicester NHS Trust	47 (9.0%)	34 (7.7%)	
Leeds Teaching Hospitals NHS Trust	41 (7.8%)	33 (7.5%)	
Barts Health NHS Trust	39 (7.4%)	32 (7.3%)	
The Newcastle upon Tyne Hospitals NHS Foundation Trust	31 (5.9%)	24 (5.5%)	
Guy's and St Thomas' NHS Foundation Trust	31 (5.9%)	29 (6.6%)	
University Hospital Birmingham NHS Foundation Trust	19 (3.6%)	14 (3.2%)	
Kings College Hospital NHS Foundation Trust	25 (4.8%)	18 (4.1%)	
South Tees Hospitals NHS Foundation Trust	15 (2.9%)	13 (3.0%)	
The Heart Hospital	1 (0.2%)	1 (0.2%)	
Elective procedure	507 (99.6%)	428 (99.5%)	1.00
General anaesthesia	514 (99.4%)	431 (99.8%)	0.63
Intra-operative echo imaging [‡] :			0.82
3D TOE	372 (58.4%)	311 (57.3%)	
2D TOE	256 (40.2%)	227 (41.8%)	
ICE	6 (0.9%)	4 (0.7%)	
None	3 (0.5%)	1 (0.2%)	
Cerebral protection device used	2 (0.4%)	0 (0.0%)	0.50
No. of devices opened for use:			0.50
0	16 (3.1%)	-	
1	436 (85.0%)	387 (89.4%)	
2	54 (10.5%)	42 (9.7%)	
3	5 (1.0%)	4 (0.9%)	
4	2 (0.4%)	0 (0.0%)	
Device used:			<0.0001*
WATCHMAN	172 (38.1%)	156 (41.7%)	
Amulet	212 (46.9%)	189 (50.5%)	
ACP	35 (7.7%)	26 (7.0%)	

Procedural characteristic†	All eligible LAAO patients (n=525)	All patients with follow-up (n=440)	p-value
Coherex - WaveCrest	3 (0.7%)	3 (0.8%)	
None	30 (6.6%)	-	
Device size, mm median (Q1,Q3) [range]	25 (22,27) [14-35]	25 (22,27) [14-35]	0.81
Fluoroscopy time, mins median (Q1:Q3) [range]	10 (7,15) [5-120]	10 (7,15) [5-120]	0.62
X-ray dose, mGray.cm ² median (Q1:Q3) [range]	1655 (576,3000) [0-20,000]	1690 (604.5,3000) [10-20,000]	0.82
Contrast dose, ml median (Q1:Q3) [range]	70 (40,110) [10-350]	70 (40,110) [10-300]	0.93
Procedural duration, mins median (Q1:Q3) [range]	75 (57,110) [0-300]	77 (60,108) [0-300]	0.84
Note:			
† Not all data fields were complete for every patient at baseline and follow up. The percentages presented in this table are calculated using the number of patients with each characteristic reported as the denominator.			
‡ multiple choices permitted			
* p-value with significant difference in variable found between those with follow-up and the whole cohort after Bonferroni corrections applied for multiple comparisons			

Appendix 4 – Outcomes

Outcomes for all eligible LAAO patients.

	In-hospital (n=525)		After discharge (6w,6m,1y,2y FU combined) (n=440)	
	Total No. of patients	% [95% CI]	Total No. of patients	% [95% CI]
Major complications:	29	5.5 [3.7:7.8]	42	9.5 [7.0:12.7]
Death	5	1.0 [0.3:2.2]	20	4.5 [2.8:6.9]
Neurological event	4	0.8 [0.2:1.9]	15	3.4 [1.9:5.6]
Pericardial effusion (requiring intervention)	11	2.1 [1.1:3.7]	-	-
Embolisation	4	0.8 [0.2:1.9]	0	0.0 [0.0:0.8]
Surgical intervention	10	1.9 [0.9:3.5]	0	0.0 [0.0:0.8]
Major vascular injury	5	1.0 [0.3:2.2]	-	-
Major bleed	10	1.9 [0.9:3.5]	11	2.5 [1.3:4.4]
MI	2	0.4 [0.0:1.4]	2	0.5 [0.1:1.6]
AKI (Stage 2 or 3)	3	0.6 [0.1:1.7]	-	-
Endocarditis	2	0.4 [0.0:1.4]	1	0.2 [0.0:1.3]
Minor complications:	24	4.6 [3.0:6.7]	72	16.4 [13.0:20.2]
Device malfunction	1	0.2 [0.0:1.1]	-	-
Malposition	0	0.0 [0.0:0.7]	54	12.3 [9.4:15.7]
Minor vascular injury	3	0.6 [0.1:1.7]	-	-
Pericardial effusion (conservative treatment)	6	1.1 [0.4:2.5]	-	-
Oesophageal damage (without death/further intervention)	0	0.0 [0.0:0.7]	-	-
Procedure-related arrhythmia	5	1.0 [0.3:2.2]	-	-
Minor bleed	8	1.5 [0.7:3.0]	20	4.5 [2.8:6.9]
Peripheral embolism	0	0.0 [0.0:0.7]	0	0.0 [0.0:0.8]
AKI (Stage 1)	1	0.2 [0.0:1.1]	-	-
Any complication (minor & major combined)	49	9.3 [7.0:12.2]	109	24.8 [20.8:29.1]
Device implanted	469	93.6 [91.1:95.6]	-	-
Yes, no leak	434	86.6 [83.3:89.5]	-	-
Yes, minor leak	32	6.4 [4.4:8.9]	-	-
Yes, moderate leak	1	0.2 [0.0:1.1]	-	-
Yes, major leak	2	0.4 [0.0:1.4]	-	-
Procedural success[†]	446	89.0 [86.0:91.6]	-	-
Extended length of stay[‡]	114	22.4 [18.8:26.3]	-	-
Clinical failure	-	-	40	9.1 [6.6:12.2]
Device not in situ	-	-	26	5.9 [3.9:8.5]
LAA not sealed – large leak (≥3mm)	-	-	7	1.6 [0.6:3.3]
Neurological event	-	-	8	1.8 [0.8:3.6]
Note:				
† device implanted in absence of major complications				
‡ >1 night				




Appendix 5 – Outcomes (Time to Event Analysis)

Patient outcomes (in-hospital and after discharge as reported at any follow-up combined) for all eligible LAAO patients.

	No. of patients with event	Total follow-up (person-years)	Event rate (per 100 person-years follow-up) [95% CI]	No. of patients at risk at 1-year	1-year event-free probability (95% CI)
Major complications:					
Death	25 (4.8%)	401.9	6.2 [4.0:9.2]	167	0.947 (0.922 to 0.972)
Neurological event	19 (3.6%)	382.0	5.0 [3.0:7.8]	157	0.956 (0.933 to 0.980)
<i>Ischaemic events only</i>	10 (1.9%)	383.4	2.6 [1.3:4.8]	159	0.979 (0.961 to 0.996)
Death or neurological event	39 (7.4%)	396.6	9.8 [7.0:13.4]	164	0.921 (0.891 to 0.952)
Minor complications:					
Malposition	60 (11.4%)	373.8	16.1 [12.3:20.7]	152	0.843 (0.801 to 0.887)
Peripheral embolism	0 (0.0%)	-	-	-	-

Appendix 6 – Kaplan-Meier Curves

Kaplan-Meier curve for death (top panel), neurological event (middle panel) and death or neurological event (bottom panel): time to event (solid lines), corresponding 95% confidence limits (dashed lines), and proportions of patients event-free at 1 year (red dashed line).



Appendix 7 – Event by Device Manufacturer

Deaths (a) and neurological events (b) by device manufacturer for all eligible LAAO CtE patients.

a)

Device Manufacturer	Death	No event	TOTAL
Boston Scientific (WATCHMAN)	8	164	172
St. Jude Medical (Amulet / ACP)	15	232	247
Coherex (WaveCrest)	0	3	3
None	1	29	30
TOTAL	24	428	452

b)

Device Manufacturer	Neurological event	No event	TOTAL
Boston Scientific (WATCHMAN)	6	166	172
St. Jude Medical (Amulet / ACP)	12	235	247
Coherex (WaveCrest)	0	3	3
None	1	29	30
TOTAL	19	433	452

Appendix 8 – Cost of an LAAO Procedure

[Table A.8.1](#) identifies all the inputs and sources used to calculate the central cost. [Table A.8.2](#) provides information on the sensitivity analyses conducted to provide high and low cost ranges.

Table A.8.1: Cost of pathway for an LAAO procedure

Parameter	Usage	Unit cost	% patients	Total cost	Source
LAAO pre-operative assessment costs					
Consultant cardiologist	50 mins	£104.00 per hr	100%	£86.67	1 MDT of 2 cardiologists and 1 nurse for 15 mins per patient + pre-assessment clinic taking 20 mins cardiologist and 60 mins nurse time. Costs from PSSRU [43]
Nurse band 6	75 mins	£44.00 per hr	100%	£55.00	
Echocardiogram with contrast	1	£87.83	100%	£87.83	Imaging use from clinical experts; costs from NHS Reference costs [10]
ECG	1	£40.35	100%	£40.35	
ToE (day case)	1	£506.30	100%	£506.30	
Blood gases	1	£6.42 - £9.84	100%	£8.13	Tests from clinical experts; costs from 'Preoperative tests' by National Clinical Guideline Centre [49]
Haemostasis of prothrombin time	1	£29.42	5%	£1.56	Tests from clinical experts; warfarin use from database and costs from 'Preoperative tests' by National Clinical Guideline Centre [49]
FBC	1	£3.00	100%	£3.00	Tests from clinical experts; costs from NHS Reference costs [10]
U&E	1	£3.00	100%	£3.00	
Sub-total pre-operative assessment costs				£792	All costs include overheads
Peri-operative costs:					
Cardiologist					Operators from database, cost PSSRU [11]
Registrar					
Anaesthetist					Staffing structure from clinical experts; cost PSSRU [11]
Cath lab assistant band 3					
Echocardiographer					
Nurse					

Parameter	Usage	Unit cost	% patients	Total cost	Source
Cardiac physiologist	█		█	█	
Radiographer	█		█	█	
Procedural time in theatre	85 mins	£299 per hr	100%	£423.13	Time from database; cost from Information Services Division (ISD) cost of theatres excluding staff and consumables costs [50]
ToE or ICE	█	█	█	█	Use from database; costed as EY502 complex echocardiogram for an elective inpatient from NHS Reference costs [10]
Anaesthetic Drugs - Desflurane & Remifentanyl	1	£82.18	100%	£82.18	Drugs agreed with clinical experts; price from a submitted template
Heparin 2 hrs per surgery and 8/12 hrs after.	1	£5.80	100%	£5.80	Drugs from clinical experts; costs from BNF [51]
Cefuroxime X 2 1.5 g, 8 hours apart	1	£10.10	100%	£10.10	
Consumables	1	£500	100%	£500	One well-completed template summed to a total cost £424. A second template summed to £686 for a General Cath Lab Instrument Set at £418 and PCI consumables at £268. The experts judged this too high and we agreed to use £500 per procedure
Devices opened per patient	█	█	█	█	Number and mix of devices from dataset; cost of device from NHS Supply Chain and include VAT. An overhead of 15% was added for overheads associated with procurement and finance costs within NHS trusts. The rate was calculated from an analysis of property-related, management and admin overheads within the Scottish NHS (see ISD)

Parameter	Usage	Unit cost	% patients	Total cost	Source
					http://www.isdscotland.org/Health-Topics/Finance/Costbook/Speciality-Costs/Overhead.asp). These represent an estimate of costs to a trust to re-order, store, deliver to theatre and finance costs. Results are presented with and without this overhead.
Sub-total peri-operative costs				£8,933	All costs include overheads
Post-operative management					
Inpatient stay	1.5 days	£356 per day	100%	£567	Stay mean value from dataset; costed using mean cost for codes EY23A to C for Standard Other Percutaneous Transluminal Repair of Acquired Defect of Heart. Reference costs [10]
Transthoracic Echocardiogram	1	£1,437	0.77	£1,106	Use from database; costed as EY502 complex echocardiogram for an inpatient from NHS Reference costs [42]
Out-patient follow-up	1	£191	100%	£191	Use from clinical experts; cost Cardiac Surgery consultant-led outpatients. Reference costs [10]
Sub-total post-operative management				£1,864	All costs include overheads
GRAND TOTAL				£11,589	

Table A.8.2: Low and high cost scenarios for pathway for an LAO procedure

Scenarios	Changes from central case	New cost
Pre-operative assessment central cost £792		
Low cost	Use first quartile cost for ToE (£185 vs central value £506) and 20% decrease in all other costs.	£413
High cost	Use third quartile cost for ToE (£657 vs central value £506) and 20% increase in all other costs.	£1,000
Peri-operative costs central cost £8,933		
Low cost	Use first quartile reported for procedure time and 20% decrease in all other costs except device.	£8,162
High cost	Use third quartile reported for procedure time and 20% increase in all other costs except device.	£9,668
Post-operative management central cost £1,864		
Low cost	Use length of stay time of 0.5 days and tariff cost for Complex Echocardiogram for Congenital Heart Disease elective patient.	£913
High cost	Use 2 days length of stay and 20% increase in all other costs.	£2,666
Total cost central case and % accounted for by device		£11,589 (■)

Total case low cost and % accounted for by device	£9,488 ()
Total cost high cost and % accounted for by device	£13,334 ()

Thus the forecast cost for an LAO procedure ranges from about £9,500 to £13,300 with the device cost () per patient; () per device) accounting for about () to ()% of the total cost.